Effects of Soluble Corn Fiber Consumption on Executive Functions and Gut Microbiota in Middle to Older Age Adults: A Randomized Controlled Crossover Trial

David A. Alvarado[1,4*], Tori A. Holthaus[1*], Shelby Martell[2], Nicole L. Southey[1], Marco Atallah[4], Rhea Sarma[3], David Revilla[4], Marina Brown[4], Twinkle Mehta[3], Naiman A. Khan[1,2,3,5], Hannah D. Holscher[1,4**]

[1]Division of Nutritional Sciences, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA

[2]Neuroscience Program, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA

[3]Health and Kinesiology, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA

[4]Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA

[5]Beckman Institute of Advanced Science and Technology, Urbana-Champaign, Urbana, IL 61801, USA

[*]Shared first-authorship

[**]**Corresponding Author:** Hannah D. Holscher, 1201 West Gregory Drive, Urbana, IL 6180 (217) 300-2512, hholsche@illinois.edu

Abbreviations:

Parabacteroides distasonis (*P. distasonis*), Cambridge Neuropsychological Test Automated Battery (CANTAB), carbohydrate-active enzymes (CAZyme), Event-related potential (ERP), FDR (False Discovery Rate Adjustment, Maltodextrin (CON, control), Perceived Stress Score (PSS), Positive and Negative Affect Schedule (PANAS), Profile of Moods Survey (POMS), Reaction Time (RT), SE (Standard Error), SEM (Standard Error of the Mean), Short-chain fatty acids (SCFA), Branched-chain fatty acids (BCFA), Soluble corn fiber/ PROMITOR® Soluble Fibre™ (SCF)

Abstract

Background: Adequate dietary fiber may support cognitive function through gastrointestinal-microbiota-dependent mechanisms, but evidence from human trials is limited.

Objectives: To determine whether soluble corn fiber (SCF) improves cognition, alters fecal microbiota, and improves fermentation end-product profiles in middle- to older-aged adults with *a priori* aims.

Methods: In this randomized, double-blind, crossover trial, 42 healthy adults (45-75y) consumed SCF (18g/d fiber) or maltodextrin (CON, 22g/d) for 4 weeks, separated by a 4-week washout. Outcomes included executive function (flanker task with event-related potentials), relational memory, neuropsychological testing, mood, fecal microbiota (16S and shotgun sequencing), targeted fecal metabolomics, and gastrointestinal tolerance symptoms. Exploratory analyses tested associations between candidate microbes and metabolites with cognition using correlation, mediation, and moderation models, while microbial species and gene families facilitating SCF fermentation were characterized using predictive metagenomes, *in vitro* culturing, and shotgun metagenomics for a subsample for microbial responder profiling.

Results: *Post-hoc* comparisons indicated that SCF improved reaction times (RT) during congruent (β = -9.65, 95% CI: [-17.4, -1.88], FDR p = 0.01) and incongruent (β = -14.2, 95% CI: [-23.5, -4.95], FDR p = 0.003) flanker trials. SCF also enriched *Parabacteroides* by ~4.1-fold (β = -1.42, 95% CI [-1.74, -1.11], FDR p < 0.001). Correlations suggested inverse associations between congruent RT and acetate (ρ = -0.33) and propionate (ρ = -0.36) concentrations, and a positive association between *Parabacteroides* and acetate (ρ = 0.34) (all FDR p < 0.09). Moderation analyses suggested exploratory threshold effects of *Parabacteroides* on the SCF-RT response. Predicted metagenome functions were enriched for carbohydrate metabolism pathways and

carbohydrate-active KOs (FDR *p* < 0.05). *In vitro* culturing confirmed *Parabacteroides*

fermentation of SCF independent of cross-feeding. Microbial responders exhibited faster RT at

baseline and endpoint, alongside greater enrichment of *Parabacteroides* and CAZymes.

Conclusion: SCF consumption improved attentional inhibition, altered fecal microbiota, and

primarily enriched *Parabacteroides*. While mediation analyses did not indicate direct microbiota-

to-cognition pathways, exploratory findings suggest baseline microbial profiles may shape

responsiveness. Collectively, these results highlight SCF as a relevant dietary fiber with potential

cognitive benefits in healthy adults.

Keywords: Reaction time; Attentional inhibition; *Parabacteroides*; gut-brain; cognition; fiber;

mediation; moderation

Introduction

A healthy diet is a key determinant of metabolic health, and emerging evidence extends these benefits to brain function and cognition [1–3]. Dietary fiber is associated with reduced risk of obesity, cardiovascular disease, type 2 diabetes, and colon cancer [4,5], yet nearly 95% of Americans fail to meet recommended intake levels [6]. Further, dietary fiber provides a primary substrate for microbes residing in the gastrointestinal (GI) tract, shaping ecological community diversity and metabolic capacity [7]. Preclinical studies show that dietary fibers improve cognition [8,9], but human trials remain limited [10–12], particularly those linking the microbiota, GI-derived metabolite,s and cognitive outcomes [13]. Therefore, further evidence is necessary to comprehensively characterize the effect of dietary fiber on general and specific domains of cognitive function.

Soluble corn fiber (SCF) is a resistant maltodextrin with an average degree of polymerization (DP) between 10-12 units [14], that supports glycemic control, calcium retention, and gastrointestinal health [15–17]. Its non-viscous, water-soluble structure lacks β-linkages, yet branching of the α-linkages confers resistance to complete digestion in the small intestine (<30%) [18,19]. The undigested fraction undergoes colonic fermentation, promoting saccharolytic taxa such as *Bifidobacterium*, *Lactobacillus*, and *Parabacteroides* [20,21], increasing production of short-chain fatty acids (SCFA) across age groups [22], while reducing deleterious fermentation-end products (phenols, indoles, ammonia) [19,23]. SCFAs are increasingly recognized as key mediators of GI-brain communications through binding of free fatty acid receptors (FFAR/FFAR3) to regulate immune [24] and enteroendocrine signaling [25], modulating microglial activity and systemic inflammation[26], and stimulating vagal and serotonergic pathways [27–30].

Executive functions, including inhibitory control, are central to attention, working memory, and flexible behavior [31]. These top-down processes can be assessed through computer-

based tasks that measure a subject's ability to maintain attention while faced with distracting

stimuli, hold and manipulate information in mind, and require multi-tasking and set-shifting, while

electrophysiological markers can provide complementary insight into neural activity during such

tasks [32,33]. Given the growing evidence that microbially derived metabolites influence brain

activity [27,34–39], assessing both behavioral and neural indices provides a comprehensive overview

to evaluate dietary fiber's cognitive impact.

To address these gaps, we conducted a randomized, double-blind, placebo-controlled,

crossover trial to test the impact of daily SCF consumption in middle- to older-aged adults. The

primary aim was to determine whether four weeks of SCF consumption improved executive

function, changes in the amplitude (size) and latency (timing) of the P3 event-related potential

(ERP), as well as additional behavioral tasks assessing relational memory and neuropsychological

function. We hypothesized that SCF would enhance cognitive control and reduce the number of

neural resources required to accomplish these cognitive processes. The secondary aim examined

the effects of SCF on GI microbiota composition and fermentation metabolites, hypothesizing that

SCF would enrich health-associated taxa and metabolite profiles. Finally, the tertiary aim tested

whether the SCF-induced changes in microbial or metabolite profiles explained changes in

cognitive outcomes, hypothesizing that these changes would contribute to the cognitive benefits

induced by SCF.

Methods

Study design and intervention

This trial included two 4-week intervention periods separated by a ~4-week washout.

Participants consumed either soluble corn fiber (SCF; PROMITOR® Soluble Fibre™, 22g/d

containing 18g fiber) or a maltodextrin placebo (CON; 22g/d). The two interventions were

provided by Tate & Lyle in identical, pre-measured sachets that were indistinguishable in taste and

appearance. Participants and research staff were kept blinded until data analyses were complete.

Participants were given 35 sachets per condition and were instructed to consume it daily dissolved

in a fluid of choice. Participants recorded intake of the sachet on daily compliance logs. Unused

sachets and logs were collected at the end of each period to assess adherence. To minimize learning

effects, participants completed practice sessions at the start of each visit until at least 70% accuracy

was meet before experimental cognitive sessions were administered. Anthropometric measures,

physical activity level, demographic information, and medical history were collected at baseline

and visits 4, 5, and 6 as potential covariates. The order of cognitive task administration at each

testing visit (visits 3-6) was counterbalanced using a 2x2 Latin square design for each participant,

and all study visits and testing sessions were conducted at the University of Illinois at Urbana-

Champaign (**Figure 1**).

Participants criteria

Adults aged 45-75 years were recruited from the East Central Illinois area using email

newsletters, social media, community postings using the postal service, and flyers posted on public

transport. All participants were informed of all procedures and provided their written informed

consent before any data was collected. The study was approved by the University of Illinois

Institutional Review Board (May 2021), registered on ClinicalTrials.gov (NCT05066425), and

conducted following the principles of the Declaration of Helsinki.

Exclusion criteria included physician-diagnosed gastrointestinal or metabolic disease

(inflammatory bowel disease and diabetes), neurological disorder (dementia, Parkinson's disease,

multiple sclerosis, brain tumors, autism), colorblindness or vision not corrected to 20/20, antibiotic

use within the past month, tobacco use, food allergies, pregnancy, or lactating, BMI <18.5 or >34.9

kg/m^2, Mini-Mental State Examination <24, or if habitual dietary fiber intake was >70% of the

daily recommended intake (≥18 g/d for women, ≥27 g/d for men) using the Dietary History

Questionnaire (*DHQ3*) food frequency questionnaire.

Eligible participants agreed to maintain habitual dietary patterns and physical activity, to

avoid pro- or prebiotics supplements, and to report any changes in medications during the study.

Enrolled participants were randomized via coin toss to start each intervention (i.e., SCF or CON)

in a counterbalanced order (**Table 1**) and assigned a study ID by a trained member of the research

staff. Sachets were labeled with numeric identifiers to preserve blinding of interventions. Height

and weight were measured in triplicate without shoes and in light clothing to determine BMI using

a *SECA* stadiometer (model 240; *SECA*, Hamburg, Germany) and Tanita WB-300 Plus digital

scale (Tanita, Tokyo, Japan). Physical activity was assessed using the Godin-Shephard Leisure-

Time Exercise Questionnaire (*Godin*), which records the frequency of strenuous, moderate, and

light physical activities performed during a typical week, which are totaled into a final score using

a weighted formula [40].

Aim 1: Cognitive Outcomes

Executive function

Attentional inhibition was assessed using a modified Eriksen flanker task as previously

described [41]. Participants were asked to respond (*Current Designs*, Philadelphia, PA, USA) quickly

and accurately to the directionality of a central stimulus (3-cm tall white arrow) presented with

two flanking stimuli (arrows) on each side (83s stimulus presentation; 100ms response window;

jittered intertrial intervals of 1100, 1200, 1500ms). In congruent trial types, the flanking stimuli

matched the direction of the central arrow (<<<<<, >>>>>); during incongruent trials, flanking

stimuli opposed the central arrow (>><>>, <<><<), requiring greater inhibitory control. The task

began with 40 practice trials followed by two blocks of 200 randomized experimental trials.

Behavioral measures were accuracy (ACC) and reaction time (RT) for correct responses.

Interference effects (flanker effect) for ACC and RT were calculated, respectively, by subtracting

incongruent from congruent measures (ACC) and congruent from incongruent measures (RT).

These measures index the ability to maintain task performance when resolving conflicting

information.

Neuroelectric indices

EEG activity was recorded simultaneously during the flanker task via a Neuro-scan Quik-

cap with 64 passive, wet, sintered Ag/AgCl scalp electrodes arranged in the international 10–10

system, with electrodes placed near the outside of each eye and above and below the left eye [42]. A

midline sensor placed between CZ and CPZ served as a reference, and AFZ served as the ground.

Continuous EEG data were digitized using a Neuroscan SynampsRT amplifier at a sampling rate

of 500 Hz, amplified 500 times to an online low-pass 70-Hz filter with a direct current and a 60-

Hz notch filter. Electrode impedance values were maintained at ≤20 kohms.

Signal processing was performed in MATLAB (MathWorks, Natick, MA, version 2021b)

using EEGLab and ERPlab [43,44]. Continuous data were re-referenced to the average of two mastoid

electrodes. A trained research team member visually inspected all channels for excessive noise

during pre-processing. Channels with excessive noise were interpolated with an average of the

adjacent electrodes. Data were submitted to a 0.1 Hz high-pass Butterworth filter before eye-blink

artifacts were rejected using independent component analysis (ICA). ICA and vertical eye sensor

channel correlations greater than 0.35 were considered eye-blinks. A time window of -200 to

1200 ms around stimulus presentation was used for creating stimulus-locked epochs with a

baseline correction of -200 ms to stimulus onset. A 30-Hz low-pass filter was used. Artifacts were

detected and rejected if a moving window peak-to-peak amplitude exceeded 100 μV, using a 100-

ms window width and step. Only correct trials with >80% of artifact-free trials in all flanker task

trials were retained, and participants with excessive artifacts (>20%) were excluded ($n = 3$ CON,

$n = 4$ SCF), consistent with previous literature [45,46].

Electrodes of interest were chosen based on a collapsed localizer technique [47]. Evidence

for selection was observed from maximal voltage localization of combined baseline and post-

testing trials collapsed across condition and trial type. *Post-hoc* topographic average plots were

constructed using a stylized topographic map plugin for EEGLAB/ERPLAB [48]. The P3 component

was defined as the region of interest comprised of C1, CZ, C2, CPZ, CP1, and CP2 with a localized

peak and corresponding latency between 300 and 600ms post-stimulus onset. Amplitude and

latency were extracted to complement the analysis of the behavioral Flanker task.

Relational memory

Hippocampal-dependent relational memory was assessed using the computerized spatial

reconstruction task presentation software (*iPosition*; Neurobehavioral Systems, Berkeley, CA) [49].

Participants studied arrays of six abstract shapes on the computer screen in a randomized array for

6 seconds. The shapes were then masked by black squares for 18 seconds and could be revealed

individually by clicking on them. After a 2-second delay, the stimuli reappeared at the top of the

screen, and participants were asked to reconstruct the original array. Each participant completed

20 trials with randomized arrays. Two error metrics were used to assess performance:

misplacement error (original misplacement), calculated as the average measure of distance

between the actual and reconstructed stimuli locations, and object-location binding (accurate

single item placement), the number of times the participant correctly placed a stimulus within a

pre-defined radius.

Neuropsychological battery

Additional cognitive performance across multiple domains was assessed using the

Cambridge Neuropsychological Test Automated Battery (*CANTAB*, Cambridge Cognition Ltd)

[50,51], administered on a touchscreen tablet. The battery included the Intra-Extra Dimensional Set

Shift (IED), Stop Signal Task (SST), Rapid Visual Information Processing (RVP), and Spatial

Working Memory (SWM). The IED is a test which assesses rule acquisition and reversal,

attentional set formation, maintenance, and shifting. The RVP task assesses sustained attention,

and the SST measures response inhibition. The SWM task assesses spatial working memory.

Mood and Stress

Mood and stress were assessed using validated self-report instruments, including the

Profile of Mood States (*POMS*), the Positive and Negative Affect Schedule (*PANAS*), and the

Perceived Stress Scale (*PSS*). The *POMS* questionnaire includes 65-items that evaluates transient

mood states across six subscales (tension/anxiety, depression, anger, vigor, fatigue, and

confusion), with ratings from 0 ("not at all") to 5 ("extremely") [52,53]. *PANAS* includes 20 items

divided evenly into positive and negative affect subscales, scored from 1 ("very slightly or not at

all") to 5 ("extremely likely") [53,54]. *PSS-10* is a 10-item measure of stress over the past month,

scored from 0 ("never") to 4 ("very often") [55].

Aim 2: Gut Microbiota and Metabolite Outcomes

Fecal collection and processing

Participants provided two fecal samples at each timepoint, collected during the five days

preceding the first intervention and the final five days of each treatment and washout period.

Samples were delivered within 15 minutes of defecation using provided kits (Commode Specimen

Collection Systems, *Sage Products*) with ice packs, and coolers. Upon arrival at the laboratory,

samples were homogenized, aliquoted into cryovials for sequencing, flash-frozen in liquid

nitrogen, and stored at -80°C. Additional aliquots were prepared for metabolite analysis: SCFAs,

BCFAs, ammonia, and dry matter basis (DMB; pre-weighed aluminum tins). These aliquots were

stored at -20°C until analysis. Fecal pH was measured (*Denver Instrument*) after samples have

been aliquoted.

Fecal DNA isolation and 16S amplicon analyses

Fecal microbial DNA was extracted using the Power-Lyzer PowerSoil DNA Isolation Kit

(*QIAGEN*). DNA was verified using 1% agarose gel electrophoresis, concentrations measured

using a Qbit 3.0 Fluorometer (*ThermoFisher Scientific*), quantified from two samples collected

per timepoint per participant, and pooled in equimolar amounts before sequencing at the University

of Illinois W.M Keck Center for Biotechnology. 16S Amplicons were generated with V4 primers

(*F*: 5'-GTGYCAGMGCCGCGGTAA, *R*: 5'-GGACTACNVGGGTWTCTAAT) and sequenced

on an Illumina NovaSeq 6000 SP (2x250 nt), producing ~1 billion reads. Sequences with quality

scores >25 were processed with *DADA2* [56] integrated in *QIIME2* (v2023.7) [57]. Sequences were

denoised and resolved into amplicon sequence variants (ASVs) using the *SILVA* 138-99

(515F/806R) naïve Bayes reference classifier [56,58]. Samples were normalized to 350,000 reads;

curves plateaued at this depth indicating adequate coverage (**Supplemental Figure 1**). Rarefaction

was performed with the *vegan* v2.6.8 [59], filtering 1,521 ASVs (13%, primarily singletons or zero-

count features) and retaining 10,373 ASVs. Alpha diversity and beta diversity were calculated with

phyloseq (v1.48.0) [60], and Faiths phylogenetic diversity (PD) with *picante* (v1.8.2). Taxonomic

summaries were created at the genus and phylum levels for downstream analyses.

Microbial Metabolites

Fecal dry matter was measured according to the Association of Official Analytical

Chemists, 1984, methods [61]. Ammonia concentrations were measured following the procedure of

Chaney and Marbach [62]. Aliquots for SCFA and BCFA were weighed, acidified with 2N

hydrochloric acid, and stored at -20°C until analysis. Before quantification, samples were thawed

at room temperature for 15 minutes and centrifuged at 13,000rcf for 10 min, then quantified using

gas chromatography mass spectroscopy (GC-MS), normalized by DMB weight [63]. Phenol and

indole were quantified, according to Flickinger et al.[64] Fecal metabolites are reported on a DMB

scale.

Digestive health

GI symptoms, bowel function, and stool characteristics were assessed using 7-day self-

reported records, questionnaires, and laboratory measures for each timepoint [65]. Participants rated

GI symptom severity (burping, cramping, bloating, gas, nausea, reflux, rumbling) on a 4-point

scale from 1 ("absent") to 4 ("severe") [66]. Bowel movements and consistency were scored using a

7-point Bristol stool scale (1- "separate hard lumps"; 2- "sausage-shaped but lumpy"; 3- "sausage-

like but with cracks on the surface"; 4- "sausage-like, smooth, and soft"; 5- "soft blobs with clear

cut edges"; 6- "fluffy pieces, mushy"; 7- "entirely liquid"). And ease of passage rated on a 5-point

scale from 1 ("very easy") to 5 ("very difficult"). In the laboratory, fresh fecal samples were

measured with a pH meter (Denver Instrument) [65], and a trained research team member recorded

stool consistency using the Bristol scale.

Aim 3: Integrative and Functional Analyses

Candidate 16S microbial genera and metabolites for integrative analyses were selected

based on statistical significance or consistent trends observed in the primary outcomes (Aim 1 and

2), with additional consideration informed by prior literature [27,34–39]. Associations between these

candidates and cognitive outcomes were examined using Spearman correlations. To assess

potential mechanistic pathways, nonparametric bootstrapped causal mediation models estimated

indirect and direct effects within a causal inference framework [67–69]. Moderation analyses were

conducted using the Johson-Neyman framework with Aiken & West's simple-slopes procedures

[70,71]. Together, these complementary approaches helped clarify whether microbial or metabolites

acted as intermediaries transmitting the treatment (mediation) or as variables altering the strength

or direction of the treatment's effect (moderation).

In vitro isolated culturing

Parabacteroides distasonis (*P. distasonis*; strain 31_2, deposited as *Porphyromonas* sp.

HM-169) was provided from the Biodefense and Emerging Infections Research Resources

Repository (BEI Resources, NIAID, NIH) and maintained anaerobically in brain heart infusion

(BHI) and chopped-meat broth. Growth assays followed an adaptation of Garcia-Bayona et al. [72]

using M9 supplemented with 50 mg/L L-cysteine, 5 mg/L hemin, 2.5 µg/L vitamin K1, 2 mg/L

FeSO4·7H2O, 5 µg/L vitamin B12. Treatments included glucose (0.25% wt/vol), CON (0.25%

wt/vol), or SCF (0.4% wt/vol). BHI served as a positive control; for negative controls, M9 with no

carbon (no growth control), and blanks (no inoculum) for each treatment (media contamination

control). Stock solutions were sterile-prepared, filter-sterilized (0.22 µm), and stored at 4 °C.

Three separate *P. distasonis* overnight cultures were inoculated into M9 solutions prepared

in a 10 x 10 honeycomb plate (1:10 dilution; starting $OD_{600} = 0.1$). For each treatment there were

technical triplicates for each (3) biological replicates. Growth was monitored with the Bioscreen-

C system (600nm, every 30 min, for 25.5h, 37 °C, shaking before/after each read) (**Supplemental**

Figure 2). All samples reached the stationary phase by 14h; therefore, analyses were restricted to

the first 14h. OD values were blank-corrected and growth rates (µ) calculated at 2 h intervals.

Exploratory metagenomics

Predictive metagenomics for the full cohort were inferred from 16S data using *PICRUSt2*

(v2.5.3) [73] with default parameters (*picrust2_pipeline.py*) [73,74]. *KEGGREST* (v112.1) was used to

extract carbohydrate metabolism pathways (map00010, 00030, 00500, 00620, 00650) and

carbohydrate-active KOs (KO01176, 01223, 01210, 01190, 01187, 012348). Stratified KO files

were used to assess genus-level contributions to functional shifts across conditions.

Six participants' fecal samples were selected for responder metagenomic analyses from the

SCF intervention. Microbial responder status was determined based on changes in

Parabacteroides abundance following SCF (**Supplemental Figure 3**). Shotgun metagenomic

sequencing was performed at the W. M. Keck Center for Biotechnology (University of Illinois

Urbana-Champaign). Libraries were pooled, quantified by qPCR, and sequenced on half of a 10B

lane for 151 cycles from both ends of the fragments using a NovaSeq X Plus with V1.0 sequencing

kits. FastQ files were demultiplexed (*bcl2fastq* v2.20), adapters (CTGTCTCTTATACACATCT)

were trimmed from the 3'-end of the reads, and base quality scores were scored using Sanger

encoding (*ASCII offset* of 33). Data pre-processing was performed on the University cluster (Carl

R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign) using

KneadData (v0.12.0) for quality control and host DNA removal (*KneadData* 20230405 release).

Trimmomatic (v0.39) removed low-quality bases, *Tandem Repeat Finder* (TRF) removed noise

from repetitive sequences, and *FastQC* (v0.11.9) generated quality reports.

Following Huttenhower BioBakery pipelines [75–77], taxonomic profiling was performed

using *MetaPhlAn* (v4.0.6) [76], with *Bowtie2* (v2.5.0) aligning reads against the

*ChocoPhlAnSGB*_202212 reference. Functional profiles were generated using *HUMAnN* (v3.7) [75]

with the *ChocoPhlAn* nucleotide database (v201901b) and *UniRef90* protein database (Nov 2024).

Profiles were merged (*merge_metaphlan_tables.py*) to produce relative abundance and read counts

[76]. Descriptive analyses compared the log fold change between responders and non-responder's

delta values, retaining gene families with >2-fold change targeted filtering for carbohydrate

metabolism-related terms yielded 217 candidate families.

Carbohydrate-active enzymes (CAZymes) were annotated using the CAZy database [78,79]

and *run_dbcan* (v4.0.0)[80], incorporating *HMMER* (*dbCAN_HMMdb*), *DIAMOND* (CAZy protein

sequences), and *dbCAN-sub* for substrate prediction validated against PUL (Polysaccharide

Utilization Loci) datasets. Reads were pre-processed (*Trim Galore* v0.6.0, *Kraken2* v2.1.1),

assembled into contigs ≥1000 bp (*MEGAHIT* v1.2.9), and annotated with *Prokka* (v1.4) before

CAZyme assignment. Clean reads were mapped back to coding sequences (*BWA* v0.7.17-r1188,

Samtools v1.7, *Bedtools* v2.27.1), and abundances normalized to transcripts per million (TPM)

using *dbcan_utils* scripts [80]. Workflow was conducted on a Linux computer (128 GB RAM)

utilizing *Anaconda* (v23.7.3) environment.

Statistical analyses

General approach. Target enrollment was determined using *a priori* power calculations

(*G-Power* v3.1.9.2) [81] , estimating that 36 participants would provide 80% power (β =0.80) to

detect a small effect size ($r = 0.20$) at $\alpha = 0.05$ for Aims 1 and 2. Due to the exploratory nature of

Aim 3, results should be interpreted as hypothesis-generating and to inform effect size estimates

for future studies. To allow for attrition, 42 participants were recruited. Analyses were conducted

in *RStudio* (v2025.05.0+496; *R* v4.4.3) [82]. Significance threshold was set at $\alpha \leq 0.05$ with false

discovery rate (FDR) adjustments applied where relevant.

Data preprocessing and assumptions. Data distributions were checked using Shapiro-

Wilk's test (*stats* v4.4.3; $W > 0.9$), Q-Q plots (*ggplot2* v3.5.2) [83], skewness/kurtosis metrics

(*DescTools* v0.99.6, *e1071* v2.6), and residuals inspected visually (*performance* v0.13.0). Extreme

outliers (>3 SD; *rstatix* v0.7.20) were confirmed using a Bonferroni *outlierTest* (*car* v3.1-3) then

winsorized [84,85]. To meet model assumptions, BCFAs POMS, PANAS, and Godin were square

root transformed; SCFAs were log-transformed. Data are reported as mean $\pm$ SEM unless

otherwise noted.

Modeling strategy. Outcomes were analyzed using linear (*lme4* v1.1.37) or generalized

(*glmmTMB* v1.1.11) mixed-effect models with treatment, time, and their interaction as fixed

effects with participant ID serving as a random intercept [*Outcome ~ Treatment * Time + (1|ID)*].

Order effects were tested and did not improve model fit; demonstrating adequate washout time,

therefore excluded. Missing data were not imputed; the mixed-effect model provides valid

estimates under the missing-at-random assumption [60]. *Post hoc* pairwise contrasts were estimated

with least-square means (*emmeans* v1.11.0) and adjusted with Benjamini-Hochberg corrections.

We reported *p*-values, estimates (β), standard error (SE), and 95% confidence intervals (CI; *stats*)

for the interaction effect in corresponding **Tables**. Analysis of variance (ANOVA; *lmerTest* v3.1.3,

car v3.1-3) and *post hoc* summaries were described when interaction effects reached statistical

significance. For non-parametric data, paired Wilcoxon Signed-Rank tests were used.

Aim 1. All measures were analyzed with mixed-effects models (*lme4* v1.1.37). Flanker task

measures (ACC, RT, and interference scores) were tested using treatment-by-time models with

congruent and incongruent trial types evaluated separately. Two flanker ACC and two P3

amplitude outcomes were winsorized; *CANTAB* delta values were compared using paired

Wilcoxon Signed-rank tests.

Aim 2. 16S analyses utilized rarefied counts for normalization. Beta diversity was assessed

by PERMANOVA (*vegan* v2.6.10; 5,000 permutations) using participant ID as the permutation

stratum, with homogeneity of dispersion (*vegan*, 5,000 permutations) tested in parallel.

Differential abundance was assessed with negative binomial mixed-effect models (*glmmTMB*

v1.1.11) comparing a null [*Taxa ~ (1|ID)*] and full [*Taxa ~ Treatment * Time + (1|ID)*] model by

a likelihood ratio test across all included taxa [86–88]. Alpha diversity and fecal metabolites were

analyzed with mixed-effects models (*lme4* v1.1.37). Gastrointestinal symptoms were compared

with a paired Wilcoxon Signed-rank test.

Aim 3. *In vitro* growth rates across treatments were modeled using a linear model (*lm*) with

treatment, timepoint (every 2h), and the interaction as fixed effects, followed by *post hoc* pairwise

contrasts [89]. Predicted KO and pathway differences were compared with *MaAsLin2* (v1.18.0) [90]

and *ggpicrust2* (v2.0.0) [91]. Correlations between cognitive and microbial outcomes were assessed

by Spearman rank tests (*stats* v4.4.3). Mediation analysis used baseline-adjusted models to (1)

predict the mediator from the Treatment [$\Delta Mediator \sim Treatment + Mediator_{Baseline}$] and (2)

predict the outcome from both the Treatment and the Mediator [$\Delta RT \sim Treatment * \Delta Mediator +$

$RT_{Baseline}$]. Causal inference was estimated using nonparametric bootstrapping (*mediation* v4.5.0;

8,000 simulations) with sensitivity analyses. Reported are the average causal mediation effect

(ACME), average direct effect (ADE), total effect, and proportion mediated. Moderation models

included treatment, centered-scaled moderator, and its interaction [$\Delta RT \sim Treatment *$

$\Delta Moderator_{z\text{-}scaled}$]; participant ID as a random intercept caused model singularity therefore

excluded. *Post-hoc* comparisons were probed using simple-slopes (*interactions* v1.2.0) with

confidence intervals (*emmeans* v1.11.0) at low (-1 SD), mean, and high (+1 SD) changes of the

moderator.

Results

Participant characteristics

The CONSORT diagram (**Figure 2**) summarizes recruitment, enrollment, and retention.

Forty-two participants were randomized, of whom 41 completed the trial (**Table 1**). All

participants completed at least one cognitive testing visit, including one who withdrew after the

first intervention period ($n = 1$ CON). Per-protocol analyses included compliant participants who

consumed >80% of intervention sachets during at least one intervention period (Aim 1; $n = 38$

CON, 39 SCF). Ten participants had unusable P3 amplitude data ($n=3$ CON; 1 at pre, 2 at post

testing) and seven for the SCF (*n* = 2 pre, 5 post testing). Two participants could not provide fecal

samples but completed the primary cognitive aims (Aim 2; *n* = 38 CON, 37 SCF).

Aim 1: Cognitive outcomes

Executive function

Flanker task ACC was high across all conditions (≥ 92%), with ANOVA showing no

treatment by time interactions for congruent (F[1, 112.25] = 0.64, *p* = 0.42) or incongruent (F[1,

110.83] = 0.39, *p* = 0.53) trial types (**Supplemental Figure 4**). RT exhibited a significant

interaction effect for both congruent (F[1, 111.2] = 6.24, *p* = 0.01) and incongruent (F[1, 110.95]

= 6.25, *p* = 0.01) trial types. *Post-hoc* comparisons indicated no baseline differences between

treatments for RT (all FDR *p* > 0.30). At endpoint, RT was faster following SCF in both congruent

(β = -9.65, SE = 3.92, 95% CI: [-17.43, -1.88], FDR *p* = 0.01) and incongruent (β = -14.2, SE =

4.68, 95% CI: [-23.49, -4.95], FDR *p* = 0.003) trials (**Figure 3**).

P3 distribution was visualized (**Supplemental Figure 5**).No interaction was observed for

P3 amplitude during congruent (F[1, 100.76] = 0.56, *p* = 0.46) or incongruent (F[1, 99.33] = 0.96,

p = 0.33) trial type, nor for peak latency during congruent (F[1, 98.69] = 0.23, *p* = 0.63) or

incongruent (F[1, 98.87] = 2.26, *p* = 0.14) trial types. No treatment-by-time interaction effect was

detected for ACC (β = -1.32, SE = 0.80, 95% CI: [-2.87, 0.24], *p* = 0.10) or RT (β = -2.69, SE =

3.12, 95% CI: [-8.78, 3.40], *p* = 0.39) interference scores.

Mood and Stress

No treatment-by-time effects were observed for any secondary outcomes. Mood subscales

and total mood disturbance (*POMS*; all *p* > 0.53), relational memory performance (*iPosition*; all *p*

> 0.45), affect (*PANAS*; all p > 0.45), and stress (*PSS*-10; p = 0.70), showed no differences

(**Supplemental Table 1**). Similarly, no effects were observed across *CANTAB* measures (all p >

0.13) (**Supplemental Table 2-5**).

Aim 2: Gut Microbiota and Metabolite Outcomes

16S Fecal microbiota

Alpha diversity showed an interaction effect with observed richness (F[1, 108.0] = 6.69,

FDR p = 0.03), with marginal effects for Faith's PD (F[1, 108.14] = 3.63, FDR p = 0.09) and none

with Shannon (FDR p = 0.26). *Post-hoc* indicated no baseline difference in richness (β = -1.04, SE

= 8.69, 95% CI: [-16.5, 18.5], FDR p = 0.91) and was reduced following SCF at endpoint (β = -

29.86, SE = 8.55, 95% CI [-47.1, -12.6], FDR p = 0.01) (**Table 5**; **Supplemental Figure 6**). Beta

diversity showed a small but statistically significant interaction across Bray-Curtis (F = 0.81, ΔR^2

= 0.005, FDR p < 0.001), Unweighted Uni-Frac (F = 0.47, ΔR^2 = 0.003, FDR p = 0.002), and

Weighted Uni-Frac (F = 1.07, ΔR^2 = 0.007, FDR p < 0.001) (**Supplemental Figure 7**). *Post-hoc*

comparisons for each metric showed differences with SCF relative to its baseline (Bray-Curtis: F

= 1.37, ΔR^2 = 0.019, FDR p < 0.001; Unweighted: F = 0.43, ΔR^2 = 0.006, FDR p = 0.03; Weighted:

F = 1.69, ΔR^2 = 0.023, FDR p < 0.001) and at endpoint relative to CON (Bray-Curtis: F = 1.39,

ΔR^2 = 0.019, FDR p < 0.001, Unweighted: F = 0.64, ΔR^2 = 0.010, FDR p = 0.005; Weighted: F =

1.69, ΔR^2 = 0.023, FDR p < 0.001). No differences were observed between baseline periods and

during the CON intervention (all FDR p > 0.85).

At the phylum level, none met the significance threshold (**Supplemental Table 6**). A total

of 260 genera were detected, 128 passed the filtering criteria (≥40% prevalence, >10 reads), and

14 met the significance threshold (FDR p < 0.05); 11 were classified as low-abundance taxa

(<0.5%) or incertae_sedis (**Supplemental Table 7)**. *Parabacteroides* enrichment was consistently

observed across 90% of participants (**Figure 4**), demonstrating an interaction effect (χ^2 = 42.0,

FDR *p* < 0.001**).** *Post-hoc* indicated no baseline differences for *Parabacteroides* between

treatments (β = 0.02, SE = 0.16, 95% CI [-0.29, 0.33], FDR *p* = 0.91) and was enriched ~4.1-log

fold by endpoint following SCF compared to CON (β = -1.42, SE = 0.16, 95% CI [-1.74, -1.11],

FDR *p* < 0.001). *Fusicatenibacter* had an interaction (χ^2 = 17.94, FDR *p* < 0.001), no baseline

differences (β = 0.14, SE: 0.19, 95% CI: [-0.23, 0.50], FDR *p* = 0.64), and ~2.7-log fold enrichment

following SCF (β = -0.97, SE: 0.18, 95% CI: [-1.34, -0.60], FDR *P*<0.001). Similarly, *Dialister*

had an interaction (χ^2 = 7.25, FDR *p* = 0.02), no baseline differences (β = 0.17, SE: 0.26, 95% CI:

[-0.33, 0.68], FDR *p* = 0.50), and ~2.4-log fold enrichment following SCF (β = -0.89, SE: 0.30,

95% CI: [-1.48, -0.30], FDR *p* = 0.03) (**Figure 4**).

Microbial metabolites

Fecal SCFAs (**Supplemental Figure 8**) and BCFAs did not statistically differ between

treatments (all *p* > 0.14; **Table 4**). Pooled total indoles (indole, 2-methylindole, 3-methylindole,

7-methylindole), indole, pooled total phenols (4-methylphenol, 4-ethylphenol, phenol), 4-

methylindole, and ammonia likewise did not show an interaction effect (all *p* > 0.32;

Supplemental Table 8).

Gastrointestinal symptoms

Symptom severity scores were generally absent to mild across conditions. No differences

were observed between treatments for changes in cramping, nausea, reflux, rumbling, or burping

(all *p* > 0.17; **Table 5**). Flatulence severity was scored increased following SCF (*p* = 0.01), while

bloating was marginally increased following SCF (p = 0.05). No interaction effect was observed

for self-reported consistency, ease of passage, bowel frequency, or fecal pH (all p > 0.22;

Supplemental Table 9).

Aim 3: Integrative and Functional Analyses

Correlation analyses

Spearman correlations were used to examine associations between selected microbial and

metabolite candidates (acetate, propionate, *Parabacteroides*, *Fusicatenibacter*, *Dialister*) and

flanker RT (**Figure 5**). For congruent trials, RT showed marginal inverse associations with acetate

(ρ = -0.33, FDR p = 0.09) and propionate (ρ = -0.36, FDR p = 0.09). *Parabacteroides* was

marginally associated with acetate (ρ = 0.34, FDR p = 0.09). No genera were associated with

congruent RT (all FDR p > 0.14). For incongruent trials, no significant correlation was detected

for any candidate (all ρ < 0.23 and FDR p > 0.30) (**Supplementary Figure 9**).

Mediation analyses

Causal mediation models tested whether microbial and metabolite candidates mediated the

treatment effect on RT. For congruent trials, no candidate showed a significant indirect effect, with

proportion of the treatment effected mediated estimated less than 10.0% across all. For incongruent

trials, mediation similarly demonstrated null mediation effects with proportions estimated less than

4.1% (**Table 6**). For both congruencies, sensitivity analyses indicated that weak correlations

between mediator and outcome error terms (ρ = -0.1) reduces the mediation effect to zero.

Moderation analyses

Moderation models tested whether changes in microbial and metabolite candidates

moderated the strength of the SCF-effect on RT. No interaction was observed across candidate

moderators (all RT $p > 0.49$) except for *Parabacteroides*, showing a moderation effect with

congruent ($p = 0.05$) and incongruent RTs ($p = 0.04$). Adding *Parabacteroides* to the model

increased explained variance from $\Delta R^2 = 0.07$ (base model) to $\Delta R^2 = 0.12$ (adjusted), whereas

other markers contributed less than 1% (**Table 7**).

Post-hoc simple slopes provided further resolution of the moderation effect from

Parabacteroides. For congruent trials, SCF treatment was associated with faster RT when

Parabacteroides changes were small (-1SD: $\beta = -29.51$, SE = 8.76, $t = -3.37$, 95% CI: [-47.0, -

12.03], $p < 0.001$), but not when *Parabacteroides* change was near the mean (0 SD; $\beta = -9.74$, SE

= 8.27, $t = -1.18$, 95% CI: [-26.2, 6.76], $p = 0.24$) or when increases were much larger (+1 SD: β

= 10.03, SE = 16.27, $t = 0.62$, 95% CI: [-22.5, 42.51], $p = 0.54$).

For incongruent trials, the same pattern emerged, SCF was associated with faster RTs at

smaller *Parabacteroides* increases ($\beta = -32.36$, SE = 10.59, $t = -3.06$, 95% CI: [-53.5, -11.2], $p <$

0.001), but not at the mean ($\beta = -7.30$, SE = 10.0, $t = -0.73$, 95% CI: [-27.3, 12.7], $p = 0.47$) or

larger enrichments ($\beta = 17.75$, SE = 19.68, $t = -0.90$, 95% CI: [-21.5, 57.0], $p = 0.37$) (**Figure 7**).

In vitro culturing of P. distasonis

P. distasonis was confirmed to grow with SCF in isolation displaying a distinct growth

kinetics with significant media effect ($F[2,42] = 9.39$, $p < 0.001$), time ($F[6,42] = 239.6$, $p < 0.001$),

and interaction ($F[12,4] = 32.7$, p < 0.001). Growth on glucose and CON showed a short lag phase

(<1h), and a rapid log phase reaching stationary phase within 5-6h (glucose: $OD_{600} = 0.59$, 5.5h;

CON: $OD_{600} = 0.54$, 5h). Growth on SCF exhibited a two-phase diauxic growth pattern: a slower

and smaller initial phase reaching $OD_{600} = 0.31$ at 6h, followed by a ~2h lag, then a second log

phase that peaked at $OD_{600} = 0.61$ by 14h. *Post-hoc* comparisons showed that SCF had

significantly lower growth rates at 2h (all FDR $p < 0.001$) and 4h (vs. glucose, FDR $p = 0.03$; vs.

CON, FDR $p = 0.01$) relative to controls. By 6h, no differences were detected across treatments.

At 8-10h, SCF had higher growth rates compared to controls (all FDR $p < 0.001$), and remained

higher at 12h (vs. glucose, FDR $p = 0.002$). By 14h, growth stabilized with no differences detected

between treatments (**Figure 8**).

Predictive functional metagenomic analyses

Unstratified KEGG Orthology (KO) analysis detected *N*-glycan biosynthesis and α-

linolenic acid metabolism pathways significantly enriched following SCF at endpoint (all FDR *p*

< 0.01). Unstratified EC (enzyme commission) analysis detected 23 enzyme functions that differed

between treatments (all FDR $p < 0.05$) (**Supplemental Figure 10**). Significant pairwise

differences were observed only for SCF compared with its baseline and CON at endpoint.

MaAsLin2 detected 2,701 carbohydrate-metabolism KOs associated with SCF at endpoint (FDR

$p < 0.05$). Pairwise comparisons showed significant differences in 1,778 KOs during the SCF

intervention, 4 during CON intervention, and none between baselines. Among the top SCF-

associated KOs, 18 showed contribution from *Parabacteroides* including glycan degradation and

complex carbohydrate utilization and two from *Fusicatenibacter* (**Supplemental Figure 11**).

Responder shotgun metagenomics analyses

Shotgun genus-level profiles confirmed that *Parabacteroides* increased in responders (Δ =

13.6%) and slightly decreased in non-responders (Δ = -0.4%), consistent with 16S results. At the

species level, *P. distasonis* increased in responders ($\Delta = 10.9\%$) and remained undetectable in non-responders, while *P. merdae* also increased in responders ($\Delta = 2.7\%$) and decreased in non-responders ($\Delta = -0.4\%$). *F. saccharivorans* negligibly increased in responders ($\Delta = 0.1\%$), compared to a larger increase in non-responders ($\Delta = 2.2\%$). *D. hominis* ($\Delta = 1.4\%$) and *D. invisus* (0.3%) increased in non-responder, while only *D. invisus* was detected and decreased in responders ($\Delta = -0.3\%$). Ordination by responder type were also observed using Bray-Curtis and Jaccard indices (**Supplemental Figure 12**).

Functional analyses with *HUMAnN* showed an increase in carbohydrate metabolism-related KOs among responders (UDP-glucose 6-dehydrogenase, α-amylases, hexokinase), while non-responders demonstrated a lack of presence in these KOs (**Figure 9**). Genus- (**Supplemental Figure 13)** and species-level time comparisons (**Figure 10**) in responders showed increased contributions from *P. distasonis* to multiple carbohydrate-active gene families, including glycoside hydrolases (GHs), α-amylases, and hexokinase. Analyses using CAZy annotations to provide further resolution of GH families and subfamilies between groups. Of 228 GH families detected, those with positive log fold changes in responders were isolated (**Supplemental Figure 14**). Several GH families were enriched (GH43_8, GH43_33, GH25, GH24, GH179, GH13_9, GH130_2, GH12) and showed positive spearman rho values with *Parabacteroides* abundances (**Supplemental Figure 15**).

Microbial responders demonstrated faster RT across the SCF intervention for both congruent ($\Delta = -0.90$ms) and incongruent ($\Delta = 2.7$ms) trials. In contrast, non-responders exhibited slower baseline RT but demonstrated larger SCF-induced improvements (congruent $\Delta = -32.1$ms, incongruent $\Delta = -31.8$ms). Parallel changes were observed in SCFAs; responders had higher baseline SCFA levels and was increased in both groups for acetate (responders $\Delta = 66.4$ vs. non-

responders Δ = 71.6 µmol/g DMB) and propionate (responders Δ = 20.9 vs. non-responders Δ =

28.6 µmol/g µmol/g DMB). (**Table 8**).

Discussion

In this randomized crossover trial, SCF improved attentional inhibition, reflected by faster

RT without compromising accuracy on both congruent and incongruent flanker task trial types.

Effects were domain-specific to attentional inhibition, with no changes in relational memory, rule

acquisition and reversal, set shifting, sustained attention, response inhibition, or spatial working

memory observed (*Aim 1*). SCF also shifted fecal microbial diversity, selectively enriching

Parabacteroides, numerically increasing fecal acetate, and yielded mild GI symptoms, consistent

with its role as a fermentable and generally well tolerated fiber (*Aim 2*). Further, SCF had no effect

on P3 amplitude or latency, mood, or stress. Exploratory analyses did not identify any mediators

but suggested that *Parabacteroides* may conditionally influence SCF-related RT improvements.

Shotgun metagenomics identified *P. distasonis* as the primary responsive, while *in vitro* culturing

independently confirmed its capacity to metabolize SCF independent of cross-feeding (*Aim 3*).

Attentional inhibition is a core domain of cognitive control that can naturally and

insidiously decline with aging [31], underscoring the need for dietary strategies to preserve healthy

cognitive aging. Few clinical trials have assessed the impact of dietary fiber on cognition while

integrating microbiome outcomes. Here, SCF selectively supported attentional inhibition, reflected

by faster RT in congruent and incongruent flanker trials, with no changes in other cognitive

outcomes. This domain-specific pattern reinforces the concept that gut-brain communication can

influence higher-order cognitive processes. Another randomized trial among 84 adults with

overweight and obesity observed greater accuracy, but not RT, during a modified flanker task

following 12 weeks of daily avocado consumption (12.8-16 grams fiber) relative to a control

providing 3.2 – 4 grams fiber daily [92]. Additional analyses showed an increase in α-diversity and

enriched *Faecalibacterium, Lachnospira*, and *Alistipes* and 18% greater fecal acetate, 70%

greater stearic acid, and 98% greater palmitic acid concentrations due to fiber-rich avocado

consumption, however, no mediation or moderation analyses were conducted [93]. Another nutrition

trial reported mood benefits with 16 g inulin/day for 12 weeks versus 16 g maltodextrin among

adults with obesity, particularly among individuals exhibiting a specific microbial signature,

however, no effects were observed on inhibitory control, working memory, or cognitive flexibility

regardless of changes in the gut microbiota [39]. Other lifestyle interventions, such as increased

physical activity, have been shown to improve flanker RT acutely, with one randomized trial

among 106 healthy-weight adults showing improvements in both congruent (458 ms vs 475 ms)

and incongruent (528 ms vs 547 ms) paradigms following 30 min of high-intensity aerobic exercise

compared with seated rest [94]. Together, these studies suggest that cognition effects are domain-

and context-specific, shaped by factors such as fiber type, population characteristics, physical

activity status, and intervention duration, which complicates direct cross-study comparisons but

underscores nutrition as a potential modifiable factor for cognitive health.

Consistent with previous SCF trials, *Parabacteroides* was enriched following the

intervention [21,95,96]. The convergence of 16S and shotgun metagenomes strengthens the confidence

that this enrichment reflects a biological response rather than a methods artifact. In responders, *P.*

distasonis abundance was inversely related to *Bacteroides vulgatus*, suggesting possible ecological

competition under SCF exposure. Predictive and shotgun metagenomics indicated increased

carbohydrate metabolism pathways and glycan degradation capacity, with CAZy highlighting the

enrichment of *Parabacteroides*-linked GHs (GH35, GH43, and GH73) [97,98]. *P. distasonis*-specific

GHs (GH144 and GH13) involved in the hydrolysis α-glycosidic bonds were also detected [97,98].

CAZymes serving similar functions are typically organized within PULs, gene clusters that coordinate sensing, import, and degradation of dietary glycans [99]. The enrichment of these CAZymes likely reflects an activation of SCF-targeting PULs, enabling *P. distasonis* to maintain a competitive niche in the large intestine. Our *in vitro* experiment supported this metabolic capacity, showing that *P. distasonis*, with no prior SCF exposure, fermented SCF in a diauxic pattern, consistent with the mixture of fiber and non-fiber starches in the formula. Together, these findings position *Parabacteroides* as a primary degrader of SCF, although mechanistic insights remain limited.

These findings are consistent with the ISAPP definition of a prebiotic: "a substrate that is selectively utilized by host microorganisms, conferring a health benefit" [100]. SCF met these criteria by inducing a small shift in the GI microbiota, selective utilization by *Parabacteroides*, and conferring a cognitive benefit in healthy older adults. *Parabacteroides* responded to SCF in 90% of the healthy cohort, consistent with the 'Health-Associated Core Keystone' (HACK) index [101], which identified *P. distasonis, P. merdae*, and *F. saccharivorans* as core and stability-associated taxa [78]. Prior work links *P. distasonis* with anti-inflammatory effects, gut barrier protection [102–104], and neuroactive metabolite production (e.g., GABA) [105], all processes relevant to gut-brain communication. Although *Parabacteroides* did not directly mediate cognitive benefits in this study, its consistent response to SCF highlights its role as a keystone taxon in healthy older adults [97,102–104,106,107].

In this study, fecal SCFAs did not reach statistical significance, however, their directional changes align with prior dietary fiber interventions and remain plausible candidates for gut-brain signaling given their ability to cross and modulate the blood-brain barrier's structural integrity [34,35,108–111]. Prior human studies show that colonic SCFA delivery influences anticipatory brain

reward responses and attenuates cortisol reactivity to psychosocial stress [35]. Despite biological

plausibility, in this study, mediation and moderation models did not support fecal SCFAs as either

mediators or moderators of the SCF effect. However, moderation analyses did suggest that the

SCF effect on RT may have depended on the magnitude of change in *Parabacteroides*. Greater

RT improvements were observed when *Parabacteroides* increases were small to modest, whereas

larger increases were not associated with faster RTs. Furthermore, microbial responders

consistently performed quicker at baseline and endpoints, while non-responders exhibited larger

improvements from SCF for RT speeds. These exploratory findings suggest that *Parabacteroides*

may exert a context-dependent influence, but its enrichment may not be linearly beneficial for

cognitive performance.

Secondary taxa provided additional exploratory context. *Dialister* was the only genus to

suggest a potential adverse mediation effect, whereas *Fusicatenibacter* showed the largest

proportion mediated. Bacillota members (e.g., *Fusicatenibacter*) are capable of cross-feeding on

substrates released by members of the Bacteroidota phylum [112] (e.g., *Parabacteroides*), producing

beneficial metabolites including acetate, lactate, formate, and succinate [113]. Potentially,

Fusicatenibacter may have had the role of the main secondary consumer working with

Parabacteroides in response to SCF. Microbial responders had higher baseline levels of *F.*

saccharivorans and showed negligible enrichment with SCF, whereas non-responders exhibited a

relatively larger enrichment. In contrast, *D. invisus* and *D. hominis* were enriched only in non-

responders and remained below detectable levels in responders. A prior study linked

Fusicatenibacter saccharivorans with executive and visuospatial functions with community-

dwelling older adults [114], whereas *Dialister invisus* was found more abundant in older adults with

mild cognitive impairment [114]. These patterns suggests that baseline microbial composition and

differential responsiveness may contribute to cognitive variability, though mechanistic inferences

remain preliminary.

The study has several limitations. First, the cohort was predominantly white, female, and

highly educated, which may restrict generalizability. Mediation and moderation analysis were

exploratory and did not fully account for the crossover design in its statistical framework and

utilized change and baseline adjustments. Shotgun metagenomics was limited to a small subset of

responders and non-responders, reducing power to detect subtle effects. The absence of systemic

samples prevent assessment of circulating SCFAs or other metabolites, while the targeted

metabolomics panel may have overlooked additional relevant compounds (e.g., tryptophan

catabolites). Although participants agreed to maintain their habitual diets, inter-individual dietary

variation may have introduced unmeasured noise into microbiome and metabolite outcomes.

Despite these limitations, the study provides novel evidence linking SCF to selective cognitive

benefits, supported by exploratory insights into microbial and SCFA response.

In conclusion, four weeks SCF improved RT in middle aged and older adults and induced

a small microbiota shift dominated by *Parabacteroides*. Exploratory moderation suggested a

threshold effect, with RT benefits most evident at smaller changes in *Parabacteroides*. Notably,

cognitive improvements were also observed in non-responders with negligible *Parabacteroides*,

indicating that cognitive benefits are unlikely to hinge on a single taxon but may instead depend

on the ecological context and balance between health associated keystone microbes (e.g.,

Parabacteroides and *Fusicatenibacter*) for contributing complementary routes to induce GI-brain

interactions [115]. These findings position SCF as a dietary fiber with potential cognitive relevance,

while underscoring the need for multi-omics, untargeted metabolomics, dosing trials, and systemic

biomarker assessments to refine mechanistic models and advance precision nutrition strategies for

cognitive health.

Acknowledgments

We thank Dr. Michael J. Miller for his expertise, equipment, and facility to conduct the *in vitro*

culturing experiment. We also thank Dr. Pratik Banerjee and his graduate students (Papri Suraya

Rahman and Edwin Valenzuela De Leon) for providing the *P. distasonis* strain and assisting with

the equipment set-up. We are also grateful to the HDH graduate students: Alexis Baldeon, Marahi

Perez-Tamayo, Nadine Veasely, and Maria Sanabria-Veaz; HDH staff: Eva Cornman, Myra

Esmail, Karen Gutierrez, and Tehila Abdiel; and NAK graduate students Shelby Keyes and John

Kim, as well as the undergraduate research assistants from HDH and NAK laboratories, for their

assistance during the appointments, sample processing, and data management.

Author Contributions

HDH, NAK, DAA and TAH: designed the research; MDB and TM: recruited and enrolled

participants and coordinated study procedures; DAA: conducted the *in vitro* experiment; DAA,

TAH, SM, TM and RS: conducted the experiments and testing appointments; MA, DR and DAA:

managed biological samples collection and storages; DAA and TAH: managed study data; DAA

and NS: prepared data for bioinformatic pipelines; DAA and TAH: analyzed the data: DAA, TAH,

NAK and HDH: wrote the manuscript; NAK and HDH: had primary responsibility for final

content. All authors read and approved the final manuscript.

Author Disclosures: The authors report no conflict of interest.

Funding: This work was supported by Tate & Lyle Ingredients Americas LLC and the USDA

NIFA, Hatch Project (1026591, to HDH).

Data Availability: Data described in the manuscript, code book, and analytic code will be made

available upon request.

References

1.   Morris MC, Wang Y, Barnes LL, Bennett DA, Dawson-Hughes B, Booth SL. Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study. *Neurology*. 2018;90(3):E214-E222. doi:10.1212/WNL.0000000000004815

2.   Perim Baldo M, Aboussaleh Y, Turrini A, et al. Adherence to a Mediterranean-Style Diet and effects on Cognition in Adults: A Qualitative evaluation and Systematic Review of Longitudinal and Prospective Trials. 2016;3:1. doi:10.3389/fnut.2016.00022

3.   Khan NA, Raine LB, Donovan SM, Hillman CH. IV. The cognitive implications of obesity and nutrition in childhood. *Monogr Soc Res Child Dev*. 2014;79(4):51-71. doi:10.1111/mono.12130

4.   Cho SS, Qi L, Fahey GC, Klurfeld DM. Consumption of cereal fiber, mixtures of whole grains and bran, and whole grains and risk reduction in type 2 diabetes, obesity, and cardiovascular disease. *American Journal of Clinical Nutrition*. 2013;98(2):594-619. doi:10.3945/ajcn.113.067629

5.   Trock B, Lanza E, Greenwald P, Lanza E, Greenwald P. *REVIEW Dietary Fiber, Vegetables, and Colon Cancer: Critical Review and Meta-Analyses of the Epidemiologic Evidence*. https://academic.oup.com/jnci/article/82/8/650/882222

6.   Gov D. *Dietary Guidelines for Americans Make Every Bite Count With the Dietary Guidelines*. https://www.

7.   Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. *Microbiome*. 2015;3(1). doi:10.1186/s40168-015-0094-5

8.   Fleming SA, Monaikul S, Patsavas AJ, Waworuntu R V., Berg BM, Dilger RN. Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig. *Nutr Neurosci*. 2019;22(7):499-512. doi:10.1080/1028415X.2017.1415280

9.   Gronier B, Savignac HM, Miceli M Di, et al. Increased cortical neuronal responses to NMDA and improved attentional set-shifting performance in rats following prebiotic (B-GOS s) ingestion. doi:10.1016/j.euroneuro.2017.11.001

10.   Khan NA, Raine LB, Drollette ES, Scudder MR, Kramer AF, Hillman CH. Dietary Fiber Is Positively Associated with Cognitive Control among Prepubertal Children. *J Nutr*. 2015;145(1):143-149. doi:10.3945/JN.114.198457

11.   Hassevoort KM, Lin AS, Khan NA, Hillman CH, Cohen NJ. Added sugar and dietary fiber consumption are associated with creativity in preadolescent children. *Nutr Neurosci*. 2020;23(10):791-802. doi:10.1080/1028415X.2018.1558003

12.   Naveed S, Venäläinen T, Eloranta AM, et al. Associations of dietary carbohydrate and fatty acid intakes with cognition among children. *Public Health Nutr*. 2020;23(9):1657-1663. doi:10.1017/S1368980019003860

13.   Cryan JF, O KJ, M Cowan CS, et al. The Microbiota-Gut-Brain Axis. *Physiol Rev*. 2019;99:1877-2013. doi:10.1152/physrev.00018.2018.-The

14.   Stewart ML, Nikhanj SD, Timm DA, Thomas W, Slavin JL. Evaluation of the effect of four fibers on laxation, gastrointestinal tolerance and serum markers in healthy humans. *Ann Nutr Metab*. 2010;56(2):91-98. doi:10.1159/000275962

15.   Shuan W, Tan K, Fen P, et al. The Role of Soluble Corn Fiber on Glycemic and Insulin Response. doi:10.3390/nu12040961

766   16.   Jakeman SA, Henry CN, Martin BR, et al. Soluble corn fiber increases bone calcium
767   retention in postmenopausal women in a dose-dependent manner: A randomized crossover
768   trial. *American Journal of Clinical Nutrition*. 2016;104(3):837-843.
769   doi:10.3945/ajcn.116.132761
770   17.   Klosterbuer AS, Hullar MAJ, Li F, et al. Gastrointestinal effects of resistant starch,
771   soluble maize fibre and pullulan in healthy adults. doi:10.1017/S0007114513000019
772   18.   LinAmy AHM, Nichols BL, Quezada-Calvillo R, et al. Unexpected high digestion rate of
773   cooked starch by the Ct-maltase-glucoamylase small intestine mucosal α-glucosidase
774   subunit. *PLoS One*. 2012;7(5). doi:10.1371/journal.pone.0035473
775   19.   Vester Boler BM, Rossoni Serao MC, Bauer LL, et al. Digestive physiological outcomes
776   related to polydextrose and soluble maize fibre consumption by healthy adult men. *British
777   Journal of Nutrition*. 2011;106(12):1864-1871. doi:10.1017/S0007114511002388
778   20.   Maathuis A, Venema K, Hoffman A, Evans A, Sanders L. The effect of the undigested
779   fraction of maize products on the activity and composition of the microbiota determined in
780   a dynamic in vitro model of the human proximal large intestine. *J Am Coll Nutr*.
781   2009;28(6):657-666. doi:10.1080/07315724.2009.10719798
782   21.   Whisner CM, Martin BR, Nakatsu CH, et al. Soluble corn fiber increases calcium
783   absorption associated with shifts in the gut microbiome: A randomized dose-response trial
784   in free-living pubertal females. *Journal of Nutrition*. 2016;146(7):1298-1306.
785   doi:10.3945/jn.115.227256
786   22.   Arroyo MC, Laurie I, Rotsaert C, Marzorati M, Risso D, Karnik K. Age-Dependent
787   Prebiotic Effects of Soluble Corn Fiber in M-SHIME® Gut Microbial Ecosystems. *Plant
788   Foods for Human Nutrition*. 2023;78(1):213-220. doi:10.1007/s11130-023-01043-z
789   23.   Holscher HD, Gregory Caporaso J, Hooda S, Brulc JM, Fahey GC, Swanson KS. Fiber
790   supplementation influences phylogenetic structure and functional capacity of the human
791   intestinal microbiome: Follow-up of a randomized controlled trial. *American Journal of
792   Clinical Nutrition*. 2015;101(1):55-64. doi:10.3945/ajcn.114.092064
793   24.   Brown AJ, Goldsworthy SM, Barnes AA, et al. The orphan G protein-coupled receptors
794   GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids.
795   *Journal of Biological Chemistry*. 2003;278(13):11312-11319.
796   doi:10.1074/jbc.M211609200
797   25.   Cani PD, Lecourt E, Dewulf EM, et al. Gut microbiota fermentation of prebiotics
798   increases satietogenic and incretin gut peptide production with consequences for appetite
799   sensation and glucose response after a meal. *American Journal of Clinical Nutrition*.
800   2009;90(5):1236-1243. doi:10.3945/ajcn.2009.28095
801   26.   Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MAR. Regulation of immune cell
802   function by short-chain fatty acids. *Clin Transl Immunology.John Wiley and Sons Inc.*
803   2016;5(4). doi:10.1038/cti.2016.17
804   27.   Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in
805   microbiota–gut–brain communication. *Nat Rev Gastroenterol Hepatol.Nature Publishing
806   Group*. 2019;16(8):461-478. doi:10.1038/s41575-019-0157-3
807   28.   Zhou SY, Guo ZN, Yang Y, Qu Y, Jin H. Gut-brain axis: Mechanisms and potential
808   therapeutic strategies for ischemic stroke through immune functions. *Front
809   Neurosci.Frontiers Media S.A.* 2023;17. doi:10.3389/fnins.2023.1081347

810   29.   Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut
811   Microbiota in Gut-Brain Communication. *Front Endocrinol (Lausanne).Frontiers Media*
812   *S.A.* 2020;11. doi:10.3389/fendo.2020.00025
813   30.   Mansuy-Aubert V, Ravussin Y. Short chain fatty acids: the messengers from down below.
814   *Front Neurosci*. 2023;17. doi:10.3389/fnins.2023.1197759
815   31.   Diamond A. Executive functions. *Annu Rev Psychol.Annual Reviews Inc.* 2013;64:135-
816   168. doi:10.1146/annurev-psych-113011-143750
817   32.   Duncan-Johnson CC. P300 latency: A new metric of information processing.
818   *Psychophysiology*. 1981;18(3):207-215. doi:10.1111/j.1469-8986.1981.tb03020.x
819   33.   Polich J. Updating P300: An integrative theory of P3a and P3b. *Clinical Neurophysiology*.
820   2007;118(10):2128-2148. doi:10.1016/j.clinph.2007.04.019
821   34.   La Torre D, Verbeke K, Dalile B. Dietary fibre and the gut–brain axis: microbiota-
822   dependent and independent mechanisms of action. *Gut Microbiome*. 2021;2.
823   doi:10.1017/gmb.2021.3
824   35.   Dalile B, Fuchs A, La Torre D, Vervliet B, Van Oudenhove L, Verbeke K. Colonic
825   butyrate administration modulates fear memory but not the acute stress response in men:
826   A randomized, triple-blind, placebo-controlled trial. *Prog Neuropsychopharmacol Biol*
827   *Psychiatry*. 2024;131. doi:10.1016/j.pnpbp.2024.110939
828   36.   Cheng J, Hu H, Ju Y, et al. Gut microbiota-derived short-chain fatty acids and depression:
829   deep insight into biological mechanisms and potential applications. *Gen Psychiatr.BMJ*
830   *Publishing Group*. 2024;37(1). doi:10.1136/gpsych-2023-101374
831   37.   Luqman A, He M, Hassan A, et al. Mood and microbes: a comprehensive review of
832   intestinal microbiota's impact on depression. *Front Psychiatry.Frontiers Media SA*.
833   2024;15. doi:10.3389/fpsyt.2024.1295766
834   38.   Haskell CF, Scholey AB, Jackson PA, et al. Cognitive and mood effects in healthy
835   children during 12 weeks' supplementation with multi-vitamin/minerals. *British Journal*
836   *of Nutrition*. 2008;100(5):1086-1096. doi:10.1017/S0007114508959213
837   39.   Leyrolle Q, Cserjesi R, D.G.H. Mulders M, et al. Prebiotic effect on mood in obese
838   patients is determined by the initial gut microbiota composition: A randomized, controlled
839   trial. *Brain Behav Immun*. 2021;94:289-298. doi:10.1016/j.bbi.2021.01.014
840   40.   Godin-Leisure-Time-Exercise-Questionnaire_070815.
841   41.   Edwards CG, Walk AM, Cannavale CN, et al. Dietary choline is related to neural
842   efficiency during a selective attention task among middle-aged adults with overweight and
843   obesity. *https://doi.org/101080/1028415X20191623456*. 2019;24(4):269-278.
844   doi:10.1080/1028415X.2019.1623456
845   42.   Chatrian GE, Lettich E, Nelson PL. American Journal of EEG Technology Ten Percent
846   Electrode System for Topographic Studies of Spontaneous and Evoked EEG Activities
847   Ten Percent Electrode System for Topographic Studies of Spontaneous and Evoked EEG
848   Activities. Published online 2015. doi:10.1080/00029238.1985.11080163
849   43.   Delorme A, Makeig S. EEGLAB: An open source toolbox for analysis of single-trial EEG
850   dynamics including independent component analysis. *J Neurosci Methods*. 2004;134(1):9-
851   21. doi:10.1016/J.JNEUMETH.2003.10.009
852   44.   Lopez-Calderon J, Luck SJ. ERPLAB: An open-source toolbox for the analysis of event-
853   related potentials. *Front Hum Neurosci*. 2014;8(1 APR):213.
854   doi:10.3389/FNHUM.2014.00213/BIBTEX

855   45.   Kamijo K, Pontifex MB, Khan NA, et al. The association of childhood obesity to
856   neuroelectric indices of inhibition. *Psychophysiology*. 2012;49(10):1361-1371.
857   doi:10.1111/J.1469-8986.2012.01459.X

858   46.   Walk AM, Edwards CG, Baumgartner NW, et al. The role of retinal carotenoids and age
859   on neuroelectric indices of attentional control among early to middle-aged adults. *Front*
860   *Aging Neurosci*. 2017;9(JUN):183. doi:10.3389/FNAGI.2017.00183/BIBTEX

861   47.   Luck SJ, Gaspelin N. How to get statistically significant effects in any ERP experiment
862   (and why you shouldn't). *Psychophysiology*. 2017;54(1):146-157.
863   doi:10.1111/PSYP.12639

864   48.   Pontifex MB. Stylized Topographic Map Plugin for EEGLAB/ERPLAB.

865   49.   Horecka KM, Dulas MR, Schwarb H, Lucas HD, Duff M, Cohen NJ. Reconstructing
866   relational information. *Hippocampus*. 2018;28(2):164-177. doi:10.1002/hipo.22819

867   50.   Langley C, Sahakian B, Robbins T. Cambridge neuropsychological test automated battery
868   (cantab). *SAGE Publications Ltd*. 2023;0:435-468.

869   51.   Wild K V., Musser ED. The cambridge neuropsychological test automated battery in the
870   assessment of executive functioning. In: *Handbook of Executive Functioning*. Springer
871   New York; 2014:171-190. doi:10.1007/978-1-4614-8106-5_11

872   52.   Stephen J. Gibson. The Measurement of Mood States in Older Adults. *The Journals of*
873   *Gerontology: Series B*. 1997;52B(4):167-174.

874   53.   Boyle GJ, Helmes E, Matthews G, Izard CE. Measures of Affect Dimensions. In:
875   *Measures of Personality and Social Psychological Constructs*. Elsevier Inc.; 2015:190-
876   224. doi:10.1016/B978-0-12-386915-9.00008-5

877   54.   Humboldt S von, Monteiro A, Leal I. Validation of the PANAS: A Measure of Positive
878   and Negative Affect for Use with Cross-National Older Adults. *Rev Eur Stud*.
879   2017;9(2):10. doi:10.5539/res.v9n2p10

880   55.   Lee EH. Review of the psychometric evidence of the perceived stress scale. *Asian Nurs*
881   *Res (Korean Soc Nurs Sci)*. 2012;6(4):121-127. doi:10.1016/j.anr.2012.08.004

882   56.   Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2:
883   High-resolution sample inference from Illumina amplicon data. *Nat Methods*.
884   2016;13(7):581-583. doi:10.1038/nmeth.3869

885   57.   Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible
886   microbiome data science using QIIME 2. *Nat Biotechnol.Nature Publishing Group*.
887   2019;37(8):852-857. doi:10.1038/s41587-019-0209-9

888   58.   Yilmaz P, Parfrey LW, Yarza P, et al. The SILVA and "all-species Living Tree Project
889   (LTP)" taxonomic frameworks. *Nucleic Acids Res*. 2014;42(D1). doi:10.1093/nar/gkt1209

890   59.   Morton JT, Marotz C, Washburne A, et al. Establishing microbial composition
891   measurement standards with reference frames. *Nat Commun*. 2019;10(1).
892   doi:10.1038/s41467-019-10656-5

893   60.   McMurdie PJ, Holmes S. Phyloseq: An R Package for Reproducible Interactive Analysis
894   and Graphics of Microbiome Census Data. *PLoS One*. 2013;8(4).
895   doi:10.1371/journal.pone.0061217

896   61.   Kenneth Helrich. *Official Methods for Analysis of the Association of Official Analytical*
897   *Chemists*.; 1990.

898   62.   Chaney AL, MEP. Modified Reagents for Determination of Urea and Ammonia. *Clin*
899   *Chem*. 1962;8(2):130-132.

63. Holscher HD, Doligale JL, Bauer LL, et al. Gastrointestinal tolerance and utilization of
agave inulin by healthy adults. *Food Funct*. 2014;5(6):1142-1149.
doi:10.1039/c3fo60666j
64. Flickinger EA, Schreijen EMWC, Patil AR, et al. Nutrient digestibilities, microbial
populations, and protein catabolites as affected by fructan supplementation of dog diets
Get access Arrow. *J Anim Sci*. 2003;81(8):2008-2018.
65. Holscher HD, Chumpitazi BP, Dahl WJ, et al. Perspective: Assessing Tolerance to
Nondigestible Carbohydrate Consumption. *Advances in Nutrition*. 2022;13(6):2084-2097.
doi:10.1093/advances/nmac091
66. Maki K, Rains T, Kelley K, Cook C, Schild A, Gietl E. Fibermalt is well tolerated in
healthy men and women at intakes up to 60 g/d: a randomized, double-blind, crossover
trial. *Int J Food Sci Nutr*. 2013;63(3):274-281.
67. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. *Journal of Statistical Software
Mediation: R Package for Causal Mediation Analysis*.; 2014. http://www.jstatsoft.org/
68. Chi WE, Huang S, Jeon M, Park ES, Melguizo T, Kezar A. A Practical Guide to Causal
Mediation Analysis: Illustration With a Comprehensive College Transition Program and
Nonprogram Peer and Faculty Interactions. *Front Educ (Lausanne)*. 2022;7.
doi:10.3389/feduc.2022.886722
69. Sohn MB, Li H. Compositional mediation analysis for microbiome studies. *Annals of
Applied Statistics*. 2019;13(1):661-681. doi:10.1214/18-AOAS1210
70. Aiken LS, West SG. Interaction Effects. In: *Encyclopedia of Statistics in Behavioral
Science*. Wiley; 2005. doi:10.1002/0470013192.bsa306
71. Preacher KJ, Curran PJ, Bauer DJ. *Computational Tools for Probing Interactions in
Multiple Linear Regression, Multilevel Modeling, and Latent Curve Analysis*. Vol 31.;
2006. http://www.quantpsy.org/.437
72. García-Bayona L, Comstock LE. Streamlined genetic manipulation of diverse bacteroides
and parabacteroides isolates from the human gut microbiota. *mBio*. 2019;10(4).
doi:10.1128/mBio.01762-19
73. Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome
functions. *Nat Biotechnol.Nature Research*. 2020;38(6):685-688. doi:10.1038/s41587-
020-0548-6
74. Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial
communities using 16S rRNA marker gene sequences. *Nat Biotechnol*. 2013;31(9):814-
821. doi:10.1038/nbt.2676
75. Beghini F, McIver LJ, Blanco-Míguez A, et al. Integrating taxonomic, functional, and
strain-level profiling of diverse microbial communities with biobakery 3. *Elife*. 2021;10.
doi:10.7554/eLife.65088
76. Blanco-Míguez A, Beghini F, Cumbo F, et al. Extending and improving metagenomic
taxonomic profiling with uncharacterized species using MetaPhlAn 4. *Nat Biotechnol*.
2023;41(11):1633-1644. doi:10.1038/s41587-023-01688-w
77. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation.
Genome Biol. 2011;12(6). doi:10.1186/gb-2011-12-6-r60
78. Drula E, Garron ML, Dogan S, Lombard V, Henrissat B, Terrapon N. The carbohydrate-
active enzyme database: Functions and literature. *Nucleic Acids Res*. 2022;50(D1):D571-
D577. doi:10.1093/nar/gkab1045

79. Cantarel BI, Coutinho PM, Rancurel C, Bernard T, Lombard V, Henrissat B. The
Carbohydrate-Active EnZymes database (CAZy): An expert resource for glycogenomics.
Nucleic Acids Res. 2009;37(SUPPL. 1). doi:10.1093/nar/gkn663

80. Zheng J, Ge Q, Yan Y, Zhang X, Huang L, Yin Y. DbCAN3: Automated carbohydrate-
Active enzyme and substrate annotation. *Nucleic Acids Res*. 2023;51(W1):W115-W121.
doi:10.1093/nar/gkad328

81. Erdfelder E, FAul F, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1:
Tests for correlation and regression analyses. *Behav Res Methods*. 2009;41(4):1149-1160.
doi:10.3758/BRM.41.4.1149

82. R Core Team. R: A language and environment for statistical computing. *Foundation for*
Statistical Computing. Preprint posted online 2013.

83. H. Wickham. ggplot2: Elegant Graphics for Data Analysis. *Springer-VerlagNew York*.
Published online 2016.

84. Kwak SK, Kim JH. Statistical data preparation: Management of missing values and
outliers. *Korean J Anesthesiol.Korean Society of Anesthesiologists*. 2017;70(4):407-411.
doi:10.4097/kjae.2017.70.4.407

85. Kafadar K. John Tukey and Robustness. *Statistical Science*. 2003;3(18(3)):319-331.
doi:1076102419

86. Zhang X, Mallick H, Tang Z, et al. Negative binomial mixed models for analyzing
microbiome count data. *BMC Bioinformatics*. 2017;18(1). doi:10.1186/s12859-016-1441-
7

87. Sweeny AR, Lemon H, Ibrahim A, et al. A mixed-model approach for estimating drivers
of microbiota community composition and differential taxonomic abundance. *mSystems*.
Published online July 25, 2023. doi:10.1128/msystems.00040-23

88. Jamieson PE, Smart EB, Bouranis JA, et al. Gut enterotype-dependent modulation of gut
microbiota and their metabolism in response to xanthohumol supplementation in healthy
adults. *Gut Microbes*. 2024;16(1). doi:10.1080/19490976.2024.2315633

89. Zwietering MH, Jongenburger I, Rombouts FM, Van ' K, Riet T. *Modeling of the*
Bacterial Growth Curve PUm.; 1990. https://journals.asm.org/journal/aem

90. Mallick H, Rahnavard A, McIver LJ, et al. Multivariable association discovery in
population-scale meta-omics studies. *PLoS Comput Biol*. 2021;17(11).
doi:10.1371/journal.pcbi.1009442

91. Yang C, Mai J, Cao X, Burberry A, Cominelli F, Zhang L. ggpicrust2: an R package for
PICRUSt2 pre-dicted functional profile analysis and visualiza-tion. *Bioinformatics,*
YYYY.:0-0. doi:10.1093/bioinformatics/xxxxx

92. Edwards CG, Walk AM, Thompson S V., et al. Effects of 12-week avocado consumption
on cognitive function among adults with overweight and obesity. *International Journal of*
Psychophysiology. 2020;148:13-24. doi:10.1016/j.ijpsycho.2019.12.006

93. Thompson S V., Bailey MA, Taylor AM, et al. Avocado Consumption Alters
Gastrointestinal Bacteria Abundance and Microbial Metabolite Concentrations among
Adults with Overweight or Obesity: A Randomized Controlled Trial. *Journal of Nutrition*.
2021;151(4):753-762. doi:10.1093/jn/nxaa219

94. Mehren A, Luque CD, Brandes M, et al. Intensity-dependent effects of acute exercise on
executive function. *Neural Plast*. 2019;2019. doi:10.1155/2019/8608317

95. Timm DA, Thomas W, Boileau TW, Williamson-Hughes PS, Slavin JL. Polydextrose and soluble corn fiber increase five-day fecal wet weight in healthy men and women. *Journal of Nutrition*. 2013;143(4):473-478. doi:10.3945/jn.112.170118

96. Hooda S, Vester Boler BM, Rossoni Serao MC, et al. 454 pyrosequencing reveals a shift in fecal microbiota of healthy adult men consuming polydextrose or soluble corn fiber. *Journal of Nutrition*. 2012;142(7):1259-1265. doi:10.3945/jn.112.158766

97. Shimizu H, Nakajima M, Miyanaga A, et al. Characterization and Structural Analysis of a Novel exo-Type Enzyme Acting on β-1,2-Glucooligosaccharides from Parabacteroides distasonis. *Biochemistry*. 2018;57(26):3849-3860. doi:10.1021/acs.biochem.8b00385

98. Ducarmon QR, Karcher N, Tytgat HLP, et al. Large-scale computational analyses of gut microbial CAZyme repertoires enabled by Cayman. Preprint posted online January 8, 2024. doi:10.1101/2024.01.08.574624

99. Lapébie P, Lombard V, Drula E, Terrapon N, Henrissat B. Bacteroidetes use thousands of enzyme combinations to break down glycans. *Nat Commun*. 2019;10(1). doi:10.1038/s41467-019-10068-5

100. Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol.Nature Publishing Group*. 2017;14(8):491-502. doi:10.1038/nrgastro.2017.75

101. Goel A, Shete O, Goswami S, et al. Toward a health-associated core keystone index for the human gut microbiome. *Cell Rep*. 2025;44(3):115378. doi:10.1016/j.celrep.2025.115378

102. Cui Y, Zhang L, Wang X, et al. Roles of intestinal Parabacteroides in human health and diseases. *FEMS Microbiol Lett.Oxford University Press*. 2022;369(1). doi:10.1093/femsle/fnac072

103. Cuffaro B, Boutillier D, Desramaut J, et al. Characterization of Two Parabacteroides distasonis Candidate Strains as New Live Biotherapeutics against Obesity. *Cells*. 2023;12(9). doi:10.3390/cells12091260

104. Ezeji JC, Sarikonda DK, Hopperton A, et al. Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health. *Gut Microbes.Bellwether Publishing, Ltd.* 2021;13(1). doi:10.1080/19490976.2021.1922241

105. Liang Z, Di N, Li L, Yang D. Gut microbiota alterations reveal potential gut–brain axis changes in polycystic ovary syndrome. *J Endocrinol Invest*. 2021;44(8):1727-1737. doi:10.1007/s40618-020-01481-5

106. Wei W, Wong CC, Jia Z, et al. Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid. *Nat Microbiol*. 2023;8(8):1534-1548. doi:10.1038/s41564-023-01418-7

107. Liu D, Zhang S, Li S, et al. Indoleacrylic acid produced by Parabacteroides distasonis alleviates type 2 diabetes via activation of AhR to repair intestinal barrier. *BMC Biol*. 2023;21(1). doi:10.1186/s12915-023-01578-2

108. Keaney J, Campbell M. The dynamic blood-brain barrier. *FEBS Journal*. 2015;282(21):4067-4079. doi:10.1111/febs.13412

109. Van Dokkum W, Wezendonk B, Srikumar TS, Van Den Heuvel EGHM. Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and

glucose absorption in young healthy male subjects. *Eur J Clin Nutr*. 1999;53(1):1-7.
doi:10.1038/sj.ejcn.1600668

110.   Pedersen A, Sandström B, Van Amelsvoort JMM. The effect of ingestion of inulin on
blood lipids and gastrointestinal symptoms in healthy females. *British Journal of*
Nutrition. 1997;78(2):215-222. doi:10.1079/bjn19970141

111.   Dalile B, La Torre D, Kalc P, et al. Extruded Wheat Bran Consumption Increases Serum
Short-Chain Fatty Acids but Does Not Modulate Psychobiological Functions in Healthy
Men: A Randomized, Placebo-Controlled Trial. *Front Nutr*. 2022;9.
doi:10.3389/fnut.2022.896154

112.   Wang S, Mu L, Yu C, et al. Microbial collaborations and conflicts: unraveling interactions
in the gut ecosystem. *Gut Microbes*.*Taylor and Francis Ltd.* 2024;16(1).
doi:10.1080/19490976.2023.2296603

113.   Takada T, Kurakawa T, Tsuji H, Nomoto K. Fusicatenibacter saccharivorans gen. nov.,
sp. nov., isolated from human faeces. *Int J Syst Evol Microbiol*. 2013;63(PART10):3691-
3696. doi:10.1099/ijs.0.045823-0

114.   Li J, Zhu S, Wang Y, et al. Metagenomic association analysis of cognitive impairment in
community-dwelling older adults. *Neurobiol Dis*. 2023;180.
doi:10.1016/j.nbd.2023.106081

115.   Loh JS, Mak WQ, Tan LKS, et al. Microbiota–gut–brain axis and its therapeutic
applications in neurodegenerative diseases. *Signal Transduct Target Ther*.*Springer*
Nature. 2024;9(1). doi:10.1038/s41392-024-01743-1

1055

Tables

Table 1. Baseline demographic and clinical characteristics of participants randomized to treatment counterbalanced.

	Overall N = 42	Maltodextrin N = 21	Soluble Corn Fiber N = 21
Education			
High School Graduate	2 (4.8%)	0 (0%)	2 (9.5%)
Some college	6 (14%)	3 (14%)	3 (14%)
Bachelor's Degree	13 (31%)	8 (38%)	5 (24%)
Advanced Degree	21 (50%)	10 (48%)	11 (52%)
Ethnicity			
Asian	6 (14%)	3 (14%)	3 (14%)
Black or African American	3 (7.1%)	1 (4.8%)	2 (9.5%)
Mixed or Other	1 (2.4%)	0 (0%)	1 (4.8%)
White (Caucasian)	32 (76%)	17 (81%)	15 (71%)
Latino	1 (2.4%)	1 (4.8%)	0 (0%)
Sex			
Female	28 (67%)	15 (71%)	13 (62%)
Male	14 (33%)	6 (29%)	8 (38%)
Age (years)	56.2 ± 7.3	54.8 ± 6.2	57.5 ± 8.2
Fiber per 1000kcal	11.4 ± 3.4	12.0 ± 3.3	10.8 ± 3.5
BMI (kg/m²)	25.9 ± 4.0	25.4 ± 3.7	26.3 ± 4.2
Income			
Less than $10,000	1 (2.4%)	0 (0%)	1 (4.8%)
$11,000-20,000	0 (0%)	0 (0%)	0 (0%)
$21,000-30,000	0 (0%)	0 (0%)	0 (0%)
$31,000-40,000	3 (7.1%)	1 (4.8%)	2 (9.5%)
$41,000-50,000	3 (7.1%)	1 (4.8%)	2 (9.5%)
$51,000-60,000	3 (7.1%)	2 (9.5%)	1 (4.8%)
$61,000-70,000	4 (9.5%)	1 (4.8%)	3 (14%)
$71,000-80,000	5 (12%)	4 (19%)	1 (4.8%)
$81,000-90,000	1 (2.4%)	1 (4.8%)	0 (0%)
$91,000-100,000	7 (16.7%)	4 (19%)	3 (14%)
Greater than $100,000	15 (35.7%)	7 (33%)	8 (38%)

Baseline characteristics of participants enrolled and randomized into the clinical trial (N = 42), stratified by initial treatment assignment. Continuous variables are reported as mean ± standard deviation; categorical variables are reported as number of participants and percentage within each group [n (%)].

Table 2. Behavioral and ERP measures during the flanker task across treatment and time.

1089

Behavioral Flanker	Maltodextrin		Soluble Corn Fiber		Treatment x Time (Model Estimates)			
	PRE	POST	PRE	POST	β	SE	95% CI	*p*
	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*				
Accuracy (%)								
Congruent	96.9 ± 0.52 *(39)*	95.5 ± 1.37 *(39)*	97.0 ± 0.48 *(40)*	97.6 ± 0.45 *(40)*	0.65	0.81	[-0.93, 2.23]	0.42
Incongruent	92.4 ± 1.00 *(39)*	92.0 ± 1.53 *(39)*	93.6 ± 0.79 *(40)*	94.4 ± 0.70 *(40)*	-0.68	1.10	[-2.82, 1.46]	0.53
Reaction Time (ms)								
Congruent	395. ± 5.79 *(39)*	**398. ± 6.69**[a] *(39)*	400.71 ± 6.22 *(40)*	**389. ± 5.52**[b] *(40)*	-13.8	5.51	[-24.5, -3.03]	**0.01***
Incongruent	431. ± 6.62 *(39)*	**437. ± 7.77**[a] *(39)*	435.43 ± 6.88 *(40)*	**424. ± 6.35**[b] *(40)*	-16.4	6.57	[-29.2, -3.62]	**0.01***
ERP Flanker								
Amplitude (µV)								
Congruent	5.96 ± 1.73 *(39)*	6.78 ± 0.68 *(36)*	6.64 ± 0.60 *(39)*	7.07 ± 0.77 *(37)*	0.88	1.18	[-2.22, 1.01]	0.46
Incongruent	6.36 ± 1.64 *(39)*	6.77 ± 0.69 *(36)*	7.14 ± 0.65 *(39)*	7.50 ± 0.79 *(37)*	1.08	1.10	[-1.06, 3.24]	0.33
Peak Latency (ms)								
Congruent	386. ± 6.71 *(39)*	399. ± 10.18 *(36)*	394. ± 7.29 *(39)*	398. ± 7.99 *(37)*	-6.16	0.32	[-31.1, 18.7]	0.67
Incongruent	424. ± 8.34 *(39)*	443. ± 11.70 *(36)*	438. ± 9.90 *(39)*	429. ± 8.27 *(37)*	-23.0	15.4	[-53.2, 6.81]	0.14

1090
Values are means ± standard error of the mean (SEM) and sample size (n) across congruencies at each timepoint. Measures include accuracy (%), reaction time
(ms), P3 amplitude (µV), and P3 peak latency (ms). Linear mixed-effect models included participant ID as a random effect, and the fixed effects of treatment, time,
and their interaction. Reported are the treatment-by-time interaction estimates (β, Standard Error (SE), 95% confidence interval (CI), *p*-values). *Post-hoc* pairwise
comparisons were conducted within each congruency when a treatment-by-time interaction met the significance threshold ($p < 0.05$), with *p*-values adjusted using
the Benjamin-Hochberg procedure. Superscripts (a, b) denote significant *post-hoc* differences within congruency trials between treatments and time. Significance
threshold *p*: '***' <0.001, '**' <0.01, '*' <0.05, '†' <0.1.

Table 3. 16S Alpha diversity and differential abundance of genera across treatment and time.

16S ASVs	Maltodextrin		Soluble Corn Fiber		Treatment x Time (Model Summary)			
	PRE	POST	PRE	POST				
	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	Mean ± SEM *(n)*	β	SE	95% CI	FDR *p*
Genera (% of sequence)								
Bacteroides	25.2 ± 1.77 *(38)*	23.7 ± 1.90 *(38)*	27.3 ± 2.06 *(37)*	22.6 ± 2.07 *(37)*	-0.15	0.10	[-0.34, 0.05]	0.11
Faecalibacterium	10.2 ± 1.02 *(38)*	10.1 ± 1.11 *(38)*	8.66 ± 1.15 *(37)*	11.0 ± 1.30 *(37)*	0.23	0.21	[-0.18, 0.64]	0.47
Parabacteroides	2.52 ± 0.35^a *(38)*	**2.06 ± 0.24^a** *(38)*	2.09 ± 0.26^a *(37)*	**8.37 ± 0.98^b** *(37)*	**1.44**	**0.22**	[1.01, 1.88]	**<0.001***
Alistipes	3.46 ± 0.51 *(38)*	2.82 ± 0.35 *(38)*	3.88 ± 0.59 *(37)*	3.96 ± 0.69 *(37)*	0.08	0.20	[-0.31, 0.46]	0.50
Blautia	3.76 ± 0.50 *(38)*	4.52 ± 0.61 *(38)*	3.54 ± 0.42 *(37)*	3.24 ± 0.50 *(37)*	-0.27	0.13	[-0.52, -0.02]	0.10†
Agathobacter	4.16 ± 0.88 *(38)*	5.97 ± 1.17 *(38)*	3.99 ± 0.85 *(37)*	2.80 ± 0.58 *(37)*	-0.46	0.23	[-0.91, 0.01]	0.11
Subdoligranulum	2.31 ± 0.29 *(38)*	2.54 ± 0.38 *(38)*	3.24 ± 0.58 *(37)*	2.69 ± 0.49 *(37)*	-0.24	0.22	[-0.68, 0.19]	0.83
Prevotella	0.87 ± 0.41 *(38)*	1.64 ± 0.74 *(38)*	1.60 ± 0.89 *(37)*	2.13 ± 1.04 *(37)*	-0.22	0.30	[-0.81, 0.37]	0.53
Dialister	1.34 ± 0.44^a *(38)*	**1.46 ± 0.51^a** *(38)*	0.93 ± 0.34^a *(37)*	**2.10 ± 0.63^b** *(37)*	1.06	0.39	[0.29, 1.83]	**0.02***
Bifidobacterium	2.50 ± 0.53 *(38)*	2.69 ± 0.53 *(38)*	2.12 ± 0.52 *(37)*	2.09 ± 0.41 *(37)*	0.09	0.31	[-0.51, 0.70]	0.92
Fusicatenibacter	0.60 ± 0.10^a *(38)*	**0.67 ± 0.09^a** *(38)*	0.53 ± 0.11^a *(37)*	**1.79 ± 0.28^b** *(37)*	1.10	1.10	[0.59, 1.61]	**<0.001***
Alpha Diversity Metrics								
Richness	439.9 ± 19.8^a *(38)*	**438.7 ± 18.2^a** *(38)*	443.6 ± 17.6^a *(37)*	**413.7 ± 18.6^b** *(37)*	-0.76	0.29	[-1.32, -0.19]	**0.03***
Shannon	3.89 ± 0.06 *(38)*	3.88 ± 0.06 *(38)*	3.81 ± 0.06 *(37)*	3.71 ± 0.07 *(37)*	-0.08	0.07	[-0.22, 0.06]	0.26
Faith's PD	104.7 ± 1.62 *(38)*	103.9 ± 1.54 *(38)*	105.23 ± 1.54 *(37)*	101.9 ± 1.80 *(37)*	-2.43	1.28	[-4.93, 0.06]	0.09†

Values are means ± standard error of the mean (SEM) and sample size (*n*) across each timepoint. For differential abundance of 16S genera, a generalized linear mixed-effect negative binomial model included participant ID as a random effect, and the fixed effects of treatment, time, and their interaction. Reported are the treatment-by-time interaction log-scaled estimates (β, Standard Error (SE), 95% confidence interval (CI), FDR-adjusted *p*-values). For alpha diversity metrics, linear mixed-effect model. Reported are the treatment-by-time interaction estimates. *Post-hoc* was conducted if a interaction met the significance threshold (*p* < 0.05), *p*-values adjusted using the Benjamin-Hochberg procedure. Superscripts (a, b) denote significant *post-hoc* differences between treatments and time. Significance threshold *p*: '***' <0.001, '**' <0.01, '*' <0.05, '†' <0.1.

1106 **Table 4.** Fecal volatile fatty acids across treatment and time.

| Fermentation end-products (μmol/g DMB) | Maltodextrin | | Soluble Corn Fiber | | Treatment x Time (Model Estimates) | | | |
| | PRE | POST | PRE | POST | | | | |
	Mean ± SEM (n)	Mean ± SEM (n)	Mean ± SEM (n)	Mean ± SEM (n)	β	SE	95% CI	p
SCFAs								
Butyrate	43.3 ± 4.56 (38)	43.9 ± 5.26 (37)	38.8 ± 4.58 (37)	40.1 ± 3.18 (37)	0.10	0.13	[-0.16, 0.37]	0.44
Acetate	176. ± 13.9 (38)	182. ± 13.5 (37)	165. ± 13.2 (37)	202. ± 14.9 (37)	0.16	0.11	[-0.04, 0.36]	0.14
Propionate	48.1 ± 3.98 (38)	50.8 ± 4.40 (37)	47.5 ± 4.32 (37)	55.6 ± 4.72 (37)	0.14	0.10	[-0.09, 0.36]	0.23
Total SCFAs	267. ± 21.5 (38)	273. ± 21.97 (37)	255. ± 20.6 (37)	298. ± 22.3 (37)	0.15	0.11	[-0.05, 0.36]	0.15
BCFAs								
Valerate	6.44 ± 0.59 (38)	5.99 ± 0.47 (37)	6.00 ± 0.47 (37)	5.68 ± 0.48 (37)	-0.06	0.16	[-0.36, 0.24]	0.71
Isobutyrate	6.62 ± 0.54 (38)	5.97 ± 0.39 (36)	6.29 ± 0.52 (37)	5.22 ± 0.33 (37)	-0.08	0.11	[-0.30, 0.14]	0.48
Isovalerate	9.49 ± 0.82 (38)	8.30 ± 0.57 (36)	8.66 ± 0.69 (37)	7.35 ± 0.54 (37)	-0.04	0.14	[-0.31, 0.22]	0.75
Total BCFAs	22.6 ± 1.83 (38)	20.4 ± 1.31 (37)	21.0 ± 1.56 (37)	18.3 ± 1.14 (37)	-0.03	0.20	[-0.43, 0.36]	0.87

1107
1108 Values are descriptive means ± standard error of the mean (SEM) and sample size (n) across each timepoint. Total SCFAs and BCFAs are pooled measures, within
1109 respective category. Linear mixed-effect models included participant ID as a random effect, and the fixed effects of treatment, time, and their interaction. Reported
1110 are the treatment-by-time interaction estimates (β, Standard Error (SE), 95% confidence interval (CI), p-values).

1111   **Table 5.** Self-reported gastrointestinal symptoms across treatment and time.

| GI Symptoms | Maltodextrin | | Soluble Corn Fiber | | |
	PRE	POST	PRE	POST	*p*
	Median [IQR] *(n)*	Median [IQR] *(n)*	Median [IQR] *(n)*	Median [IQR] *(n)*	
Gas	1.57 [0.84] *(39)*	**1.43 [1.00]** *(39)*	1.57 [0.97] *(38)*	**1.93 [1.00]** *(38)*	**0.01***
Cramping	1.00 [0.00] *(39)*	1.00 [0.00] *(39)*	1.00 [0.00] *(38)*	1.00 [0.14] *(38)*	0.91
Bloating	1.00 [0.14] *(39)*	1.00 [0.14] *(39)*	1.00 [0.14] *(38)*	1.00 [0.32] *(38)*	0.05†
Nausea	1.00 [0.00] *(39)*	1.00 [0.00] *(39)*	1.00 [0.00] *(38)*	1.00 [0.00] *(38)*	0.17
Reflux	1.00 [0.00] *(39)*	1.00 [0.00] *(39)*	1.00 [0.03] *(38)*	1.00 [0.00] *(38)*	0.84
Rumbling	1.00 [0.16] *(39)*	1.00 [0.16] *(39)*	1.00 [0.17] *(38)*	1.00 [0.41] *(38)*	0.68
Burping	1.00 [0.16] *(39)*	1.00 [0.00] *(39)*	1.00 [0.28] *(38)*	1.00 [0.17] *(38)*	0.70

1112
1113   Values are descriptive median ± interquartile range (IQR) and sample size (n) across each timepoint. Symptom
1114   severity was rated on a 4-point scale (1 = Absent, 2 = Mild, 3 = Moderate, 4 = Severe). Reported values include *p*-
1115   values from the paired Wilcoxon Signed-Rank tests. Significance threshold *p*: '*' <0.05, '†' <0.1.
1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

 Table 6. Mediation of SCF-related changes in Flanker reaction times through fecal SCFAs and
1128 16S taxa.

				Nonparametric Bootstrap Confidence Intervals with Percentile	
Mediator	**Flanker Task**	**Effect**	**β**	**[95% CI]**	***p***
Acetate	Congruent RT	ACME	-0.57	[-2.51, 0.87]	0.48
		ADE	-13.42	[-23.7, -3.23]	0.01*
		Total effect	-13.99	[-14.0, -24.4]	0.009**
		Proportion Mediated	4.09%	[-0.08, 0.21]	0.48
	Incongruent RT	ACME	-0.44	[-2.87, 1.61]	0.72
		ADE	-17.03	[-29.4, -4.38]	0.008**
		Total effect	-17.47	[-30.1, -4.63]	0.007**
		Proportion Mediated	2.51%	[-0.11, 0.19]	0.72
Propionate	Congruent RT	ACME	-0.64	[-2.39, 0.81]	0.43
		ADE	-13.39	[-23.9, -3.30]	0.01*
		Total effect	-14.03	[-24.4, -3.78]	0.008**
		Proportion Mediated	4.57%	[-0.28, 0.08]	0.43
	Incongruent RT	ACME	-0.38	[-4.32, 0.78]	0.22
		ADE	-17.11	[-23.0, -2.36]	0.03*
		Total effect	-17.49	[-24.3, -3.77]	0.01*
		Proportion Mediated	2.22%	[-0.11, 0.54]	0.23
Parabacteroides	Congruent RT	ACME	-0.15	[-9.31, 4.27]	0.93
		ADE	-13.85	[-25.9, 0.39]	0.06
		Total effect	-14.00	[-24.3, -3.83]	0.008**
		Proportion Mediated	1.06%	[-0.36, 1.02]	0.93
	Incongruent RT	ACME	-0.48	[-12.64, 4.53]	0.86
		ADE	-17.00	[-30.5, 0.20]	0.03*
		Total effect	-17.48	[-30.0, -4.80]	0.01*
		Proportion Mediated	2.75%	[-0.34, 0.96]	0.86
Fusicatenibacter	Congruent RT	ACME	-1.40	[-4.98, 0.65]	0.19
		ADE	-12.63	[-23.0, -2.28]	0.02*
		Total effect	-14.03	[-24.3, -3.84]	0.007**
		Proportion Mediated	10.0%	[-0.06, 0.50]	0.19
	Incongruent RT	ACME	-0.72	[-4.98, 2.16]	0.59
		ADE	-16.75	[-29.1, -3.85]	0.01*
		Total effect	-17.47	[-30.0, -4.79]	0.007**
		Proportion Mediated	4.1%	[-0.18, 0.35]	0.59
Dialister	Congruent RT	ACME	0.44	[-0.89, 3.47]	0.52
		ADE	-14.44	[-25.4, -4.22]	0.006**
		Total effect	-14.00	[-24.2, -3.75]	0.007**
		Proportion Mediated	-3.15%	[-0.33, 0.08]	0.53
	Incongruent RT	ACME	0.67	[-1.26, 4.95]	0.52
		ADE	-18.15	[-31.8, -5.12]	0.007**
		Total effect	-17.49	[-30.0, -4.70]	0.007**
		Proportion Mediated	-3.8%	[-0.35, 0.11]	0.53

Mediation analysis was conducted using nonparametric bootstrapped linear regression models (R; *mediation*) to
estimate the average causal mediation effect (ACME), average direct effect (ADE), and total effects of treatment on
changes in reaction times (RT) Reported are the model estimates (β), Standard Error (SE), 95% confidence interval
(CI), (n = 37). Proportion mediated indicates the percentage of the total effect explained by the ACME pathway.
Significance threshold p: '***' <0.001, '**' <0.01, '*' <0.05, '†' <0.1.

Table 7. Moderation influence of fecal SCFAs and 16S genera on SCF-related changes in
Flanker reaction times.

Moderator	Flanker Task	Treatment x Moderator (Model Summary)						
		ΔR^2	Adj. ΔR^2	β	SE	t	[95% CI]	*p*
Acetate	Congruent RT	0.11	0.07	3.13	5.62	0.56	[-8.08, 14.3]	0.58
	Incongruent RT	0.10	0.06	2.21	6.80	0.33	[-11.4, 15.8]	0.75
Propionate	Congruent RT	0.11	0.07	0.43	5.60	0.08	[-10.76, 11.6]	0.94
	Incongruent RT	0.10	0.06	0.40	6.80	0.06	[-13.17, 14.0]	0.95
Parabacteroides	Congruent RT	**0.16**	0.12	**-19.8**	10.12	-1.95	[-40.0, 0.43]	**0.05***
	Incongruent RT	**0.15**	0.12	**-25.1**	12.24	-2.05	[-49.5, 0.63]	**0.04***
Fusicatenibacter	Congruent RT	0.10	0.06	-1.31	13.48	-0.10	[-28.2, 25.6]	0.92
	Incongruent RT	0.11	0.07	11.49	16.20	0.71	[-20.9, 43.8]	0.49
Dialister	Congruent RT	0.11	0.07	-4.49	7.39	-0.61	[-19.2, 10.3]	0.55
	Incongruent RT	0.10	0.06	0.23	8.98	0.03	[-17.7, 18.2]	0.98

1136
1137 Moderation analysis was conducted using linear regression models testing if changes in moderators explain variability
1138 in flanker reaction times (RT). Each model includes treatment, Δ moderator, and its interaction. Reported are the
1139 treatment-by-moderator estimates (β, Standard Error (SE), 95% confidence interval (CI), *p*-values). The ΔR^2 and
1140 adjusted ΔR^2 columns show the variance explained by the full model. Statistical threshold for *p*: '***' <0.001, '**'
1141 <0.01, '*' <0.05, '†' <0.1.
1142

1143

1144

1145

1146

1147

Table 8. Summary of Responder analysis across the SCF intervention.

Pilot Analyses	Non-Responder		Responder	
	PRE	POST	PRE	POST
	Mean ± SD *(n)*	Mean ± SD *(n)*	Mean ± SD *(n)*	Mean ± SD *(n)*
Genera (% of Sequences)				
Parabacteroides	0.43 ± 0.64 *(3)*	*ND (3)*	1.04 ± 0.33 *(3)*	14.61 ± 2.82 *(3)*
Dialister	1.50 ± 0.79 *(3)*	3.18 ± 3.25 *(3)*	0.25 ± 0.43 *(3)*	*ND (3)*
Fusicatenibacter	0.48 ± 0.45 *(3)*	2.69 ± 2.77 *(3)*	1.24 ± 1.65 *(3)*	1.35 ± 1.34 *(3)*
Species (% of Sequences)				
P. distasonis	0.01 ± 0.01 *(3)*	*ND (3)*	0.49 ± 0.17 *(3)*	11.38 ± 1.47 *(3)*
P. merdae	0.41 ± 0.63 *(3)*	*ND (3)*	0.55 ± 0.50 *(3)*	3.23 ± 3.67 *(3)*
P. faecis	0.01 ± 0.01 *(3)*	*ND (3)*	*ND (3)*	*ND (3)*
D. invisus	0.73 ± 0.73 *(3)*	1.00 ± 1.74 *(3)*	0.25 ± 0.43 *(3)*	*ND (3)*
D. hominis	0.77 ± 1.34 *(3)*	2.17 ± 3.75 *(3)*	*ND (3)*	*ND (3)*
F. saccharivorans	0.48 ± 0.45 *(3)*	2.69 ± 2.77 *(3)*	1.24 ± 1.65 *(3)*	1.35 ± 1.34 *(3)*
Flanker Reaction Time (ms)				
Congruent	428.9 ± 24.4 *(3)*	396.7 ± 11.6 *(3)*	363.0 ± 50.2 *(3)*	362.1 ± 42.7 *(3)*
Incongruent	456.6 ± 3.9 *(3)*	424.9 ± 14.4 *(3)*	403.9 ± 60.2 *(3)*	401.1 ± 50.2 *(3)*
SCFAs (μmol/g DMB)				
Acetate	153.8 ± 60.9 *(3)*	225.4 ± 88.9 *(3)*	180.2 ± 95.1 *(3)*	246.6 ± 59.1 *(3)*
Propionate	28.47 ± 12.2 *(3)*	57.02 ± 23.7 *(3)*	51.89 ± 23.6 *(3)*	72.81 ± 27.2 *(3)*
Demographics				
Age *(year)*	53.7 ± 7.2 *(3)*		54.3 ± 2.5 *(3)*	

Descriptive analyses of microbial responders and non-responders during the SCF intervention subsampled from the study. Data are presented as mean ± standard deviation (SD) and sample size (*n*). Metaphlan4 was used for genus and species relative abundance values (%). Species initials correspond as follows: *P = Parabacteroides*, *D = Dialister*, and *F = Fusicatenibacter*.

Figure Legend

Figure 1. Study design timeline and sample collection procedures. Participants completed six laboratory visits across two 4-week intervention periods separate by a washout. Visit 1: Eligibility (screening, consent/surveys); if eligible, they were randomized and scheduled (~2 weeks) for their Visit 2 with stool collection and diet record deployed for Visit 3 first intervention baseline. Visit 2: Practice/familiarization sessions with EEG cap placement, scheduled ~1 week before to testing visit. Visits 3 and 5: Pre-intervention testing days with the full EEG-based cognitive battery. Visits 4 and 6: Post-intervention follow-ups with the same testing battery. Stools samples were collected over the final 5-days of each intervention period and returned at the subsequent testing visit. (*Figure created using BioRender*)

Figure 2. CONSORT flow diagram of recruitment, randomization, and retention. Each "*n*" indicates the number of participants at each stage of the study. Participants were randomized to maltodextrin (CON) or soluble corn fiber (SCF) in a counterbalanced crossover design. (*Figure created using BioRender*)

Figure 3. Flanker task reaction times for both congruencies across each timepoint. Raw distributions (left) and model-derived estimated marginal means (right) of reaction times (RT, ms) are shown for (**A**) congruent trials (top row) and (**B**) incongruent trials (bottom row) across treatment and time. Statistical significance derived from *post-hoc* pairwise comparisons. FDR-adjusted *p*-values annotated as follows: ** < 0.01; * < 0.05; † < 0.1.

Figure 4. 16S microbiota composition across condition and participants. (**A**) First row shows relative abundance (%) of the top 5 for phyla (left) and top 10 for genera (right) across the interventions averaged within conditions. Color gradient for genera correspond to their parent phylum. (**B**) 16S differential abundance volcan plot shows glmm model interaction estimates with effect size increasing from the center dashed vertical line). The y-axis corresponds to the significance of the genera, higher meaning more significant, with a horizontal dashed line indicating the FDR $p = 0.05$ threshold. The waterfall plot (**C**) highlights patterns from statistically relevant genera at the individual level.

Figure 5. Distribution and *post-hoc* comparison of 16S selected genera. Relative abundances (% of sequences) on the left and estimated marginal pairwise comparisons (Emmeans, right; log scale) of *Parabacteroides* (A), *Fusicatenibacter* (B), and *Dialister* (C) across conditions. *Post-hoc* analyses show FDR-adjusted *p* between treatment at endpoint. Statistical significance is annotated as follows: *** < 0.001; ** < 0.01; * < 0.05; † < 0.1.

Figure 6. Spearman correlation heatmap of reaction times, fecal SCFAs, and 16S genera following soluble corn fiber intervention. Heatmap displays Spearman's coefficients (ρ) between the markers of interest and the flanker task reaction times ($n = 37$; SCF arm only). Positive correlations are orange, negative correlations blue, with intensity reflecting the magnitude. Spearman *p*-values were FDR adjusted. Statistical significances are annotated as follows: *p* *** < 0.001, † < 0.1.

Figure 7. Interaction between 16S *Parabacteroides* and SCF effect on RTs. Moderation outcomes, with the top row (**A**) for congruent RTs, and the bottom row (**B**) for incongruent RTs (ΔRT, ms) plotted as a function of change in the relative abundance of *Parabacteroides* (z-scored). On the left, lines represent model-predicted simple slopes for maltodextrin (blue) and SCF (orange) groups with vertical dotted lines marking the conditional effects at low (-1 standard deviation (SD)), centered mean, and high (+1 SD) of Δ*Parabacteroides*. On the right, panels show estimated pairwise differences (SCF-CON) from emmeans contrasts of the moderator values; the vertical line indicates no change, crossing indicates no statistical significance. Significance threshold p * <0.05.

Figure 8. Growth rates of *Parabacteroides distasonis* cultured in M9 supplement with SCF compared to controls. The relative log growth curve of *P. distasonis* (A) in M9 minimal medium supplemented with different carbohydrate sources. OD_0 represents the initial optical density (OD_{600}) at time zero. Each curve represents a mean biological replicate (N = 3), and error bars indicate propagated standard deviations. The mean growth rate (B), calculated as the slope of ln(OD) over sequential 2-hour intervals, cut off at 10-hrs. Bars represent average growth rate across replicates. Significance threshold p: '***' < 0.001, '**' < 0.01, '*' < 0.05, '†' < 0.1, 'NS' > 0.1.

Figure 9. Abundance of carbohydrate metabolism-associated gene families comparison between responders and non-responders at endpoint of the SCF intervention. Heatmap displaying the abundance of carbohydrate metabolism-related gene families annotated by HUMAnNv3.0 across six participants (N = 6), stratified by responder (R1–R3) and non-responder (NR1–NR3) status. Genes families shown (rows) were selected from a total of 1,180 unique carbohydrate-associated gene families based on a log_2 fold change > 2 in mean abundance between responders and non-responders [log2(R/NR)]. The top 40 gene families are presented. Abundance values were row-scaled using Z-score normalization to emphasize relative variation across samples. Orange indicates higher abundance, and blue indicates lower abundance for each gene.

Figure 10. Responders' species-level profile contributions over time to carbohydrate metabolism gene family abundances. Heatmaps showing the contribution of individual species (columns) to the abundance of 40 carbohydrate metabolism-associated gene families (rows) of microbial responders. The top panel (A) shows the baseline timepoint while the bottom panel (B) shows the endpoint of the SCF intervention. Gene abundance was row-normalized using Z-scores to highlight species-level contributions, with orange indicating higher and blue indicating lower abundance for each gene.

Figure 1. Study design timeline and sample collection procedures. Participants completed six laboratory visits across two 4-week intervention periods separate by a washout. Visit 1: Eligibility (screening, consent/surveys); if eligible, they were randomized and scheduled (~2 weeks) for their Visit 2 with stool collection and diet record deployed for Visit 3 first intervention baseline. Visit 2: Practice/familiarization sessions with EEG cap placement, scheduled ~1 week before to testing visit. Visits 3 and 5: Pre-intervention testing days with the full EEG-based cognitive battery. Visits 4 and 6: Post-intervention follow-ups with the same testing battery. Stools samples were collected over the final 5-days of each intervention period and returned at the subsequent testing visit. (*Figure created using BioRender*)

Figure 2. CONSORT flow diagram of recruitment, randomization, and retention. Each "*n*" indicates the number of participants at each stage of the study. Participants were randomized to maltodextrin (CON) or soluble corn fiber (SCF) in a counterbalanced crossover design. (*Figure created using BioRender*)

Figure 3. Flanker task reaction times for both congruencies across each timepoint. Raw distributions (left) and model-derived estimated marginal means (right) of reaction times (RT, ms) are shown for (**A**) congruent trials (top row) and (**B**) incongruent trials (bottom row) across treatment and time. Statistical significance derived from *post-hoc* pairwise comparisons. FDR-adjusted *p*-values annotated as follows: ** < 0.01; * < 0.05; † < 0.1.

Figure 4. 16S microbiota composition across condition and participants. (**A**) First row shows relative abundance (%) of the top 5 for phyla (left) and top 10 for genera (right) across the interventions averaged within conditions. Color gradient for genera correspond to their parent phylum. (**B**) 16S differential abundance volcan plot shows glmm model interaction estimates with effect size increasing from the center dashed vertical line). The y-axis corresponds to the significance of the genera, higher meaning more significant, with a horizontal dashed line indicating the FDR $p = 0.05$ threshold. The waterfall plot (**C**) highlights patterns from statistically relevant genera at the individual level.

Figure 5. Distribution and *post-hoc* comparison of 16S selected genera. Relative abundances (% of sequences) on the left and estimated marginal pairwise comparisons (Emmeans, right; log scale) of *Parabacteroides* (A), *Fusicatenibacter* (B), and *Dialister* (C) across conditions. *Post-hoc* analyses show FDR-adjusted *p* between treatment at endpoint. Statistical significance is annotated as follows: *** < 0.001; ** < 0.01; * < 0.05; † < 0.1.

Figure 6. Spearman correlation heatmap of reaction times, fecal SCFAs, and 16S genera following soluble corn fiber intervention. Heatmap displays Spearman's coefficients (ρ) between the markers of interest and the flanker task reaction times ($n = 37$; SCF arm only). Positive correlations are orange, negative correlations blue, with intensity reflecting the magnitude. Spearman p-values were FDR adjusted. Statistical significances are annotated as follows: p *** < 0.001, † < 0.1.

Figure 7. Interaction between 16S *Parabacteroides* and SCF effect on RTs. Moderation outcomes, with the top row (**A**) for congruent RTs, and the bottom row (**B**) for incongruent RTs (ΔRT, ms) plotted as a function of change in the relative abundance of *Parabacteroides* (centered and scaled). On the left, lines represent model-predicted simple slopes for maltodextrin (blue) and SCF (orange) groups with vertical dotted lines marking the conditional effects at low (-1 standard deviation (SD)), centered mean, and high (+1 SD) of Δ*Parabacteroides*. On the right, panels show estimated pairwise differences (SCF-CON) from emmeans contrasts of the moderator values; the vertical line indicates no change, crossing indicates no statistical significance. Significance threshold *p* * <0.05.

Figure 8. Growth rates of *Parabacteroides distasonis* cultured in M9 supplement with SCF compared to controls. The relative log growth curve of *P. distasonis* (A) in M9 minimal medium supplemented with different carbohydrate sources. OD_0 represents the initial optical density (OD_{600}) at time zero. Each curve represents a mean biological replicate (N = 3), and error bars indicate propagated standard deviations. The mean growth rate (B), calculated as the slope of ln(OD) over sequential 2-hour intervals, cut off at 10-hrs. Bars represent average growth rate across replicates. Significance threshold *p*: '***' < 0.001, '**' < 0.01, '*' < 0.05, '†' < 0.1, 'NS' > 0.1.

Figure 9. Abundance of carbohydrate metabolism-associated gene families comparison between responders and non-responders at endpoint of the SCF intervention. Heatmap displaying the abundance of carbohydrate metabolism-related gene families annotated by HUMAnNv3.0 across six participants (N = 6), stratified by responder (R1–R3) and non-responder (NR1–NR3) status. Genes families shown (rows) were selected from a total of 1,180 unique carbohydrate-associated gene families based on a log_2 fold change > 2 in mean abundance between responders and non-responders [log2(R/NR)]. The top 40 gene families are presented. Abundance values were row-scaled using Z-score normalization to emphasize relative variation across samples. Orange indicates higher abundance, and blue indicates lower abundance for each gene.

Figure 10. Responders' species-level profile contributions over time to carbohydrate metabolism gene family abundances. Heatmaps showing the contribution of individual species (columns) to the abundance of 40 carbohydrate metabolism-associated gene families (rows) of microbial responders. The top panel (A) shows the baseline timepoint while the bottom panel (B) shows the endpoint of the SCF intervention. Gene abundance was row-normalized using Z-scores to highlight species-level contributions, with orange indicating higher and blue indicating lower abundance for each gene.